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Abbreviations 
 
List of abbreviations mentioned in the text. Genes are written in italic capitals, whereas proteins in 
non-italic capitals. 
 
ARF                             alternative reading frame 
ATP                             adenine tri-phosphate 
Bp                                base pair 
CCND1                       cyclin D1 
CCND3                       cyclin D3 
CCNE1                       cyclin E 
CDK2, 4, 6                  cyclin dependent kinase 2, 4, 6 
CDKN1A                     cyclin dependent kinase inhibitor 1A (p21CIP1) 
CDKN1B                     cyclin dependent kinase inhibitor 1B (p27KIP1) 
CDKN1C                     cyclin dependent kinase inhibitor 1C (p57KIP2) 
CDKN2A                     cyclin dependent kinase inhibitor 2A (p16INK4A) 
                                    or the alternative reading frame (p14ARF) 
CDKN2C                    cyclin dependent kinase inhibitor 2C (p18INK4C) 
CGH                           comparative genomic hybridization 
CIN                             chromosome instability 
DNA                           deoxyribonucleic acid 
E2F                             E2F transcription factor 
ERRBB2                      erythroblastic leukemia viral oncogene homolog 2 (HER2) 
FISH   fluorescence in situ hybridization 
G1                               gap phase 1 
G2                               gap phase 2 
GAP                            GTPase activating protein 
GDP                            deoxyguanosine diphosphate 
GEF                             guanine exchange factor 
GTP                             deoxyguanosine trisphosphate 
kb                                kilo base 
kDa                              kilo Dalton 
LOH                            loss of heterozygosity 
MDM2                         murine double minute-2 protein 
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M phase                       mitotic phase 
MPNST                       malignant peripheral nerve sheath tumor 
mRNA                         messenger RNA 
NF1                             the disorder Neurofibromatosis type 1, or the protein neurofibromin 
(in order to distinguish between these two the protein will be designated                     
neurofibromin).  
RAS                              rat sarcoma virus 
RB                                retinoblastoma 
RNA                             ribonucleic acid 
R point                         restriction point 
S phase                        synthesis phase 
TGF-β                         transforming growth factor β 
TMA                           tissue micro array 
TSG                             tumor suppressor gene 
TP53                            tumor protein 53 
UV                               ultraviolet  
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Summary 
 
Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant inherited disorders, 
and carriers are at greatly increased risk of developing malignant peripheral nerve sheath tumours 
(MPNST). The NF1 patients are carriers of a germline mutation in the NF1 gene, which encodes the 
protein neurofibromin. This protein is in normal cells responsible for the deactivation of RAS through 
GTP-hydrolysis and inactivation of the gene will lead to hyperstimulation of the MAP-kinase 
pathway. However, inactivations of both NF1 alleles are also found in the benign precursor lesions, 
neurofibromas, showing that additional genetic events are necessary for malignant transformation.  
 
MPNSTs usually have complex karyotypes showing numerous chromosomal aberrations. We have 
previously shown recurrent copy number gains and losses, including frequent loss of 9p and 13q, and 
gain of 17q. The target gene for the 9p losses is the CDKN2A and for the 17q gain there is evidence 
for TOP2A as one target gene. The target gene(s) for the 13q losses remains unknown, although the 
RB1 is a possible candidate.  
In the present study we have analyzed topoisomerase II α, TOP2A and other chromosome 17 probes in 
a series of MPNSTs and neurofibromas (n=32) by metaphase- and inter-phase fluorescence in situ 
hybridization, FISH. Excess of TOP2A signals, relative to the centromere signals of the same 
chromosome, was found in 12 tumors. This support that gene amplification of TOP2A partly explain 
the previously observed increased expression of TOP2A in this type of tumors. The fact that TOP2A is 
the molecular target of several well-established chemotherapeutic agents, and that no consensus for 
therapy, except surgery, exists, underline the importance of these findings. In search for an additional 
and more distal amplicon at 17q we first analyzed distal loci by interphase FISH and, indeed we found 
amplification in four MPNST with normal copy number of the 17 centromere and TOP2A. By a global 
genomic approach, so called COBRA-FISH, we thereafter identified four MPNST with chromosomal 
breakpoints involving 17q. This pinpointed the region of interest for further FISH studies using BAC 
probes in order to identify the gene(s) targets.  
The second part of this study focused on in situ expression taking advantage of tissue microarray 
(TMA) as a tool for analyses of a large clinical series.  
Previous studies have suggested that some central cell cycle components, in particular deficient p16, 
contribute to the development of MPNST. A selected set (n=11) of cell cycle components and 
proliferation markers (n=2) as well as the neurofibromin protein were analyzed by 
immunohistochemistry on a TMA with tissue cores from 106 MPNSTs and 3 neurofibromas. The 
thirteen 5um parallel sections, hybridized with the individual antibodies, were each scanned with high 
resolution before visual scoring was done from the digital images. The expression data revealed that 
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topoisomerase IIα (TOP2A) and Ki-67 are indeed expressed in most MPNSTs. Fewer tumors than 
expected had positive score of tumor protein 53 (TP53). Generally, expression of cyclins and CDKs 
were common among MPNSTs, leading to phosphorylated retinoblastoma (RB1) and G1/S transition. 
The cyclin-CDK-complex inhibitors were on the other side absent from most MPNSTs, confirming the 
suspicion of lost control of the cell cycle checkpoint at G1-phase.  
 
MPNST is a highly aggressive cancer disease for which no standard therapy, except surgery, exists. 
A molecular classification of these tumors in combination with the clinical and pathological 
evaluations may aid in improved treatment of these patients. The current study has added new 
knowledge to the understanding of the molecular biology of MPNST.  
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Preface – a chain of coincidence? 
 
 
ven today we're not fully aware of our origin. Throughout evolution the last 2-3 billions 
years, we have evolved via many different species. But how the first cell did come to life is 
still a mystery. It can be hard to comprehend that life is just a process of random consequence, when 
life is so complex. Even bacteria, the smallest form of life, have thousands of genes and proteins to 
control at any time. Take for instance the naturally existing amino acids. Human proteins consist of 20 
different amino acids. All of these are left-handed amino acids (L-enantiomers). In fact, almost all life 
on Earth has come to use left-handed amino acids exclusively, rather than their mirror-image, the 
right-handed forms (Figure 1). Could this be a coincidence through evolution, or are we created this 
way? Some new evidence support evolution. Scientists working on a meteorite discovered that it 
contained an excess of left-handed amino acids. It seems like some process is favoring L-enantiomers, 
and that this has been going on even before the origin of life on earth, and probably before the 
formation of our Solar System1.  
 
 
 
 
Figure 1. Left-and right-handed versions of the amino acid alanine. A meteoritic excess of L-alanine has been shown not 
to be from terrestrial contamination, so life's chemical left-handedness may be extraterrestrial. 
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Introduction 
Cancer and evolution 
 
   A single celled organism has to "fight" with other organisms in its habitat to survive. Only 
organisms that are able to feed and propagate well will continue to exist. If the environment is 
changing, for example to a colder climate, the organism has to be able to comprehend these new 
surroundings, or to change its habitat. If it also can multiply and reproduce itself into new organisms 
having the same qualities as it self, it will be a winner through the eyes of evolution. A cancerous cell 
has these qualities, and becomes a threat to the multicellular individual as it has selective advantages 
over normal cells. If there is a shortage of nourishment, the cell can adapt new ways of getting more 
than its neighboring competing cells. This can be done through growth of new blood vessels that 
cancerous cells actually can guide toward them in a process called angiogenesis. With this single 
improvement the cell is now able to multiply faster than the normal cells, and is already on its way to 
generate a tumor (Figure 2). 
Key behaviors of a cancer cell were reviewed by Hanahan & Weinberg5 and are discussed on page 12. 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mutation and evolution. The red cell has by chance evolved a new beneficial quality, and has now a higher 
probability of dividing and multiply into many new cells, compared with the normal blue cells. 
 
 
Mutations 
 
The evolutionary record consists of a long series of mutations. It can be hard to imagine that a random 
chain of coincidence can give a favorable quality. Usually a mutation leads to a disadvantage for the 
organism, often with a deadly outcome. If an organism gets a mutation that has a drawback, the 
chances are that it won’t produce offspring, and the mutation will die out with the organism. Once in a 
while a cell will also get a beneficial mutation, which gives it an advantage that no other cell have, 
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analogous to Darwinian evolution. Through time this has lead a single-cellular organism to evolve to a 
multi-cellular organism, and has eventually also led to the creation of man. And also, in a stepwise 
manner, a normal cell can develop into a vicious cancerous cell (Figure 3), that will invade the entire 
body, with an unfortunate result for the person involved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Tumor development. Through a long process man has evolved from a single-celled organism.  
Tumor development also involves several steps that occur through a period of time, but at another time schedule.   
 
 
History of cancer 
 
   The process of understanding cancer did a leap forward in 1890 when David von Hansemann, a 
German pathologist discovered that the material he was working on had irregularities compared with 
normal tissue. He was studying biopsies from several neoplasms, and found that the nuclei often had 
different shapes, and that the density of them was higher than normal. He also discovered that the 
mitotic pattern was abnormal in a high number of the cells.  
   This eventually led to the somatic mutation theory of cancer, which was presented in 1914 by 
Theodor Boveri in his famous book "Zur Frage der Entstehung maligner Tumoren”. He meant that 
cancer is the result of mutations in one cell, and the development of a neoplasm comes from this cell 
and its daughter cells.  
 During the next 30-40 years many new approaches were invented, and for example the use of model 
organisms helped the scientists to great discoveries. For instance has the work on plants (e.g. 
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Arabidopsis thaliana), yeast (e.g. Saccharomyces cerevisiae), insects (e.g. Drosophila melanogaster), 
nematodes (e.g. Caenorhabditis elegans), and mice (e.g. Mus musculus) given us clues on how the 
genetic material is expressed also during the development of humans. From the 1950s some of the new 
techniques were used to examine human cells, and a new way of treating cells made it possible to 
continuously grow new clones, with the exact same genetic material as the original cell (the stem line 
concept, first defined by Winge (1930)). These include human cancer cells. Soon the benefit of using 
colchicin, a substance that arrests cells in mitosis by breaking down the spindle apparatus, together 
with the knowledge that hypotonic salt solution gave good metaphase spreads, resulted in individual 
chromosomes could be counted and analyzed. All this led to the finding of the first chromosome 
abnormality in a human cancer. Nowell & Hungerford detected in 1960 a small karyotypic marker in 
patients with chronic myeloid leukemia. The same error in breakpoint location between two 
chromosomes was repeatedly seen in cells of many human individuals. Having this mutation the effect 
always led to the development of leukemia. Nowell & Hungerford named this specific karyotype for 
the Philadelphia (Ph1) chromosome. This discovery proved that Boveri’s idea from 1914 was correct. 
It is today a dogma that cancer does start with mutations in one cell (Figure 4). A relationship between 
the type of cancer, and the often chaotic pattern of human tumor karyotype, was established by Levan 
and van Steenis in 1966, and then again by Mitelman in 1974. Different chromosomes and 
chromosome regions are involved in various neoplasms, and specific abnormalities are found to be 
general for different cancer types and diseases. 
 
 
                                                    
                                           person 1 
 
 
                                                             
 
 
 
                             Figure 4. Two specific mutations (green and blue) are pathognomonic for 
person 2                      two completely different cancer types.  
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Cell Cycle 
 
It is through regulation of the processes of cell cycling and apoptosis that a multicellular organism 
regulates the total number of cells it retains. After the developing epoch is over, the rate of 
proliferation slows down. But a single cell does have a much shorter life span than its host, so new 
genetically identical daughter cells are formed to keep up with the right amount of cells required.  
 
A cell is divided into two during the M phase (mitosis). The time between mitosis is called the 
interphase. During this phase the cell prepares it self to be divided again in the next M phase. It gains 
weight and copies its DNA. The interphase is divided into G1 phase (growth), S phase (synthesize) and 
G2 phase, where these actions take place. 
 
The progression of the cell cycle is regulated by extracellular signals as well as by internal signals that 
coordinate the various processes that take place during the different cell cycle phases. Growth factors 
for instance may act as extracellular signals that tell the cell to continue proliferation, whereas 
processes such as DNA replication and mitosis are carefully monitored by internal signals. To avoid 
conflicts of these signals, a series of control points in the cell cycle is secured through evolution. For 
example, it is critically important that the cell don’t begin mitosis until after the genome is replicated. 
The most important regulatory point is late in G1 and controls progression from G1 to S. Before 
crossing this restriction point (R-point), the cell may be in an arrested state called G0, where the cell is 
waiting for external signals for further activity. The cell can remain in G0 phase for a long period of 
time without proliferating. Leaving this phase is the start of a new cell division, which is irreversible, 
even in the absence of further growth factor stimulation. 
 
Other cell cycle checkpoints have more precise tasks. To ensure that incomplete or damaged 
chromosomes are not replicated and passed on to daughter cells, there are additional control points 
throughout the cell cycle. In the G1 checkpoint, DNA damage is allowed to be repaired. Arrest at the 
G1 checkpoint is mediated by the action of a key protein known as TP53, which is rapidly induced in 
response to damaged DNA. TP53 is the most often mutated gene in human cancers, and loss of 
function of TP53 may lead to daughter cells with damaged DNA. These cells have an increased 
frequency of mutations and general instability of the cellular genome, which contributes to cancer 
development. Germline mutations of TP53 cause the Li-Fraumeni syndrome and patients with this 
disease may develop various kinds of cancers. Somatic mutations are known to be present in more 
than half of all cancers and are often associated to poor disease outcome. If TP53 or other central 
tumor suppressor genes (such as cyclin dependent kinase inhibitors) of the cell cycle are non-
functioning, the cycle may enter too early into the next phase. Also protooncogenes, that normally 
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stimulate the cell cycle, may be mutated in cancer and thereby act as oncogenes (such as the cyclins 
and cyclin dependent kinases, Figure 5). This may lead to a continuous stimulation of the cell cycle 
and potentially to cancer development. 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The cell cycle is regulated by intra- as well as extracellular signals that monitor and 
coordinate the various processes that take place during different cell cycle phases. A major cell cycle 
regulatory point occurs late in G1 and controls progression from G1 to S. Once cells have passed this 
restriction point, they are committed to entering S phase and go through one cell division cycle. Key 
regulators to the entrance of the various phases are the CDKs, which only functions in complex with 
the correct cyclin. A set or phosphorylations and dephosphorylation events, as well as protein 
degradation processes, further control the action of these complexes.  CDKN1A and CDKN1B are 
some of the CDK-inhibitors that exist. They negatively control the cell cycle by reducing the catalytic 
activity of CDK-cyclin complexes. 
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The G2 checkpoint ensures that the DNA is properly replicated before the cell enters the M phase. In 
this manner its ensured that incompletely replicated DNA is not distributed to daughter cells. Equally 
important is making sure that the genome is replicated only once per cell cycle. Therefore control 
mechanisms exist to prevent initiation of another round of DNA replication after DNA has been 
replicated once2. This way the mother cell is divided into two equally equipped daughter cells. 
The key behaviors of cancer cells 
 
What are the steps that will transform a normal cell into a cancerous one? The capability that a single 
cell has to evolve on a micro-evolutional scale involves dynamic changes in the genome. Over time it 
has to pass through different obstacles that are necessary to develop malignant cancer. Cytogenetic 
studies have demonstrated that in many primary tumors all the cells have the same abnormal 
karyotype, suggesting a unicellular origin, the so called monoclonality theory3. This means that when a 
mutation is beneficial for a cancerous cell, all its offspring will inherit this quality. The regulatory 
machinery that helps a normal cell to live "peacefully" in harmony with the rest of the human cells is 
disrupted. The homeostasis within the cell is put out of order, and the cancerous cell is evolving into a 
more self-centered cell. It no longer lives by the rules that are necessary for a multi cell organism to 
function. Hanahan and Weinberg5 pinpointed several physiological features that characterize a cancer 
cell, shortly described in the following. 
 
1.Growth-inhibitory signals 
 
   To become a cancerous cell the normal cell has to ignore antigrowth signals from the other cells 
nearby. In a healthy multicellular organism, limited growth and proliferation is important to establish a 
dynamic working "community" of cells. The components involved in the regulation of cell cycle clock 
normally keep the cell under control, but when mutated, cells will overlook these growth-inhibitory 
signals and soon outnumber the normal cells in the area. If the retinoblastoma protein that blocks E2F 
transcription factor is mutated in such a way that it is kept from doing this, E2F will continuously 
transcribe genes stimulating the cells to premature entry into S phase4.   
 
2.Growth signals 
 
Not only does a cancerous cell have to ignore inhibitory signals, it also has to make its own growth 
stimulatory signals. A normal cell is dependent on a continually flow of growth signals from the tissue 
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around. One type of cell is telling another how to react at a certain time. This is the way cells 
communicate. When this communication is broken and a cell starts to make its own growth signals, it 
stimulates itself to proliferate. This is called autocrine stimulation. In about 25% of human tumors, the 
SOS-Ras-Raf-MAPK pathway is altered and put out of balance, leading to massive growth5,6. 
3.Apoptosis 
 
Even if cells achieve the requirements for continuous growth, they will eventually go into apoptosis. 
This is a program multicellular organisms have to eliminate cells to maintain a proper number. 
Apoptosis is also initiated if a cell has unrepairable damaged DNA. It will then be dangerous for the 
rest of the organism to let the cell continue to proliferate with severe DNA changes. Apoptosis is 
regulated by signals from the extracellular and intracellular environment. If any abnormalities are 
discovered the program will kill the cell. This is done by breaking up the cell membrane and 
degradation of the chromosomes. 
   TP53 controls apoptosis. In response to upregulated expression of the BAX protein, the 
mitochondria will release cytochrome C. Within 30-120 minutes the nucleus and the rest of the cell 
will be fragmented, and the cell will die. All the parts are absorbed by neighboring cells by controlled 
autodigestion7. 
   In more than 50% of all human cancer TP53 is mutated leading to an inactive TP53 protein8. Cells 
that normally would go into apoptosis will carry on proliferating, even if the genetic material is 
heavily disrupted. With these conditions a cancerous cell can rapidly evolve. 
 
4.Senescence 
 
Cells will eventually stop dividing. After a specific number of multiplications, a program that is 
different from apoptosis and independent from extracellular signals will turn the cell off and stop the 
chance of further proliferation. This is called senescence, and is controlled by the shortening of the 
telomeres. Under each cell cycle 50-100 bp of DNA are lost from the chromosome ends. Because loss 
of genetic material in this way would lead to devastating damages over time, an enzyme is set to 
produce new nucleotides in the ends of the chromosomes. In cancer cells expression of this enzyme, 
called telomerase, is up-regulated in 85-90%9 This gives the cancer cell the ability of limitless 
replication, in contrast to normal human cells that only have the capacity for 60-70 divisions7. 
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5.Angiogenesis 
 
Nutrition is crucial for survival. When a tumor is developing rapidly, the cells in the center will be 
further and further away from blood vessel. Without blood in the proximity, there will be no new 
supplies of nutrients and oxygen, and expansion is impossible. 
   A new tissue is formed together with the growth of new blood vessels; a carefully regulated process 
called angiogenesis. If a tumor is to grow larger than in an early stage, it must acquire angiogenic 
capabilities. 
 
6.Metastasis 
 
The final stage for a cancer cell is to spread. This is the ability to invade new tissue and to continue to 
grow there. A benign cell can only keep growing at the same place in the tissue where it originally 
developed. Treatment for this kind of tumor is done by surgical removal. When a tumor becomes 
metastatic the chances of survival drop dramatically. The new colonies of cancer cells can in principle 
settle down anywhere and develop into new tumors. These metastases are responsible for 90% of all 
human cancer deaths10. The molecular mechanisms are not well known, but clearly involve proteins 
that have to do with cell-cell adhesion, like integrins. The potential for new treatments based on 
molecular targeting is huge, exemplified with the successful treatment of chronic myelogenic leukemia 
and gastrointestinal stromal tumors with Gleevec78. 
 
Cancer, age, inheritance and environment 
 
Mutations accumulate over time, and cancer therefore may develop over a lifetime. Humans continue 
to extend the lifespan as a consequence of scientific progress. If we are to live to the age of 120-140 
years old, cancer will be even more frequent late in our lifetime because there are more time for 
mutations too occur. 
For heritable cancer types the schedules are a different. Approximately 5% of all cancers come from 
this category. Because these individuals are already born with a mutation that’s either passed on from 
a parent or a new mutation acquired in the germline, cancer may develop much earlier11. The 
retinoblastoma gene (RB1) can be found mutated among family members, who have inherited a 
mutation in one of the two alleles through the germline. If the remaining wild type RB1 allele is 
mutated, the cell lose of RB1 function completely. This is known as the “two-hit” mutation theory and 
was described by Knudson in 197113. 
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Environmental factors can influence the probability of evolving some types of cancers. For instance is 
tobacco smoke a well-known carcinogen, together with asbestos, radon, outdoor air pollution or 
exposure to radiation. Today, there is overwhelming evidence that tobacco smoking plays a major role 
in the epidemiology of lung cancer, cancers at other sites, and a variety of chronic degenerative 
diseases14,15. In a more specific sense, however, environmental factors include only the (natural or 
man-made) agents encountered by humans in their daily life, upon which they have no or limited 
personal control. The most important environmental exposures in this strict sense include outdoor and 
indoor air pollution and soil and drinking water contamination. These incidences are estimated to 
count for near 2% of all cancer records. Exposure is involuntary but can to a large extent be avoided16. 
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Neurofibromatosis type 1 
 
Neurofibromatosis type 1 was first defined by Friedrich von Recklinghausen in 1882. In 1918, Presier 
and Davenport demonstrated that neurofibromatosis type 1 was an inherited disorder and it is today 
known as one of the most common autosomal dominant disorders in humans with an incidence of 
approximately 1 in 400072. Patients with this illness have a germline mutation in the gene NF117. In 
half of the cases the mutation is inherited from one of the parents, but in the remaining half the 
mutation is new and has evolved through the germline. The patients are heterozygote for the mutation, 
and any somatic cell will become homozygote with a new mutation in the remaining wild-type allele. 
The NF1 gene encodes a protein called neurofibromin, and is expressed in the Schwann cells in the 
nervous system18,19. Schwann cells make the layers that wraps around the peripheral nerves, protecting 
and isolating the axons. Neurofibromin is also expressed in other tissues, but not as much as in 
Schwann cells. The expression is particularly high early in the development of the peripheral nerves. 
NF1 is located within the chromosome band 17q11.2, and spans 350kb DNA. It contains 60 exons that 
transcribe an mRNA product of 11-13 kb20. Neurofibromin has the properties of a GTPase activating 
protein (GAP), and therefore plays an important roll in regulating RAS in the MAP-kinase pathway. 
RAS is an oncogene, and if hyper-stimulated, it will cause the MAP-kinase to produce ectopic 
amounts of transcription factors downstream. A cell that is under continuous influence of proliferating 
stimuli will eventually lose control of the cell cycle may build a tumor. Neurofibromin’s role in this 
pathway is to regulate the activity of RAS by converting the active RAS-GTP into the inactive RAS-
GDP21-23 (Figure 6). This activity is reduced in patients with the neurofibromatosis type 1 disease 
when NF1 is mutated or if the expression of neurofibromin downregulated. RAS-GTP will stay 
constitutively activated with the GTPase activity of neurofibromin missing. 
 
NF1 is one of many tumor suppressor genes identified during the last two decades. Many tumor 
suppressors are key regulators in signaling pathways, but are only relevant in specific tissues. So non-
functioning neurofibromin in Schwann cells are extremely critical, and these are the only cell type 
where the disease develops. However, inactive NF1 have also been found in other cancer types73,74,75. 
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                                                                                                               Figure 6a. Normal gene expression  
                                                                                                                              with neurofibromin present                                    
produces a controlled cell cycle.                                    
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6b. An increased gene expression  
 caused by the mutation of the  
 neurofibromin transcribing gene NF1 
 results in a faster proliferating cell, and 
 contribute to carcinogenesis.                                                                                                              
 
 
 
 
The diagnostics of neurofibromatosis type 1 is complicated, but some of the characteristic phenotypic 
features are plexiform neurofibromas, café au lait spots, Lisch nodules, and distinctive bony lesions24 
(Figure 7). Seizures, headache and learning disabilities are also common complications for NF1 
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patients25. The phenotypes can be highly variable even among family members that are carrying the 
same mutation in the NF1 gene. Symptoms do in general seem to increase in severity and number over 
time26,27. 
 
 
             
 
 
 
   
 
 
 
 
 
 
 
 
                                         Neurofibromas                          Plexiform neurofibromas      
 
 
 
 
 
 
 
 
                                           Café au lait spots                                   Lisch nodules 
 
Figure 7. Some of the characteristic phenotypic features of neurofibromas.  
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The NF1 patients also have an increased risk for developing other cancer types, but in particular, they 
have a greatly increased risk compared to the general population in developing malignant peripheral 
nerve sheath tumor (MPNST).
MPNST 
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MPNST – malignant peripheral nerve sheath tumor 
 
   About 5% of the NF1 patients develop MPNST28 (Figure 8). In general it is a rare malignancy, with 
an incidence of 1 in every 100 000. Therefore, individuals with NF1 account for 50% of all patients 
with MPNST. The other 50% are sporadic cases. They develop MPNST when they are 20-80 years 
old, while NF1 patients usually develops MPNST at relatively young ages (15-45 years of age)29,30.  
 
 
  neurofibroma                                                                        neurofibroma                                                             
 
 
 
 
 
 
 
                                                                                                                 MPNST 
 
 
                                                                                                                                                        
 
 
 
Figure 8. A tumor that consist of a benign part, neurofibroma, and a malignant part, MPNST. A typical pattern in MPNST 
is the overwhelming amount of nuclei. 
 
At least two thirds of the MPNSTs develop from precursor lesions, the benign neurofibromas, and in 
particular from the plexiformed, or in rare cases from the dermal subtype of neurofibromas. These 
lesions contain several cell types, and evidence suggests that the MPNST develop from the Schwann 
cells. MPNSTs are of neuroectodermal origin (see below) but are classified as under soft tissue 
sarcomas. This is mainly due to the fact that many of the same complications as seen for soft tissue 
sarcomas are evident for MPNST patients. Also, many of MPNSTs develop in the extremities. 
Today, no consensus for treatment exists for this highly aggressive disease 
. 
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Peripheral nerve development 
 
The nervous system develops from the ectoderm. Here, two sets of cells derive - those of the neural 
tube, which forms the central nervous system (the spinal cord and brain, including the retina of the 
eye), and those of the neural crest which gives rise to most of the neurons and supporting cells of the 
peripheral nervous system31. Axons conduct signals from the cell body, while the multiple dendrites 
receive signals of other neurons and connect cells through synapses. Nerve fibers are usually found 
grouped together in tight parallel bundles called fascicles invested by a perineurium. Most peripheral 
nerve neoplasms are assumed to arise from cells of neuroectodermal origin, the Schwann cells. 
Schwann cells wrap its plasma 
membrane around the axon to form 
a segment of myelin sheath about 1 
mm long (Figure 9). 
But to cover the possibility that 
some of the tumors arise from nerve 
sheath cells other than the Schwann 
cell, the nonspecific term of 
MPNST is preferred over malignant 
schwannoma. Secondly, this also 
avoids the potential 
misunderstanding that MPNST arise 
from benign schwannomas that in 
reality is extraordinary rare. 
                                                                           Figure 9. A nerve cell. Schwann cells make up a myelin sheath around the    
nerve axon by wrapping its plasma membrane (taken from Ion Channels 
and the Electrical Properties of Membranes, the Cell, Fourth Edition 2001). 
 
Indications from clinical behaviors of these two neurofibromas show that plexiform neurofibromas are 
probably derived from embryonic Schwann-cell lineage, whereas dermal neurofibromas can arise from 
more mature Schwann-cell lineage 36,37 (figure 10). 
 
Neurofibroma is a heterogeneous tumor that contains every cell type that is present in normal 
peripheral nerves. These are Schwann cells, fibroblasts, perineural cells, neuronal processes, and mast 
cells. Schwannoma on the other hand is a homogeneous tumor that is composed of Schwann cells. 
Both tumors are benign and belong to WHO grade I. MPNSTs on the other hand are grade III-IV 32,38 
and have a 5 year survival rate of 34-52%36. 
MPNST 
 
25
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The evolvement of Schwann cells takes place through different stages before becoming 
mature cells. The type of tumor that forms depends of when the NF1 mutation occurs. If it is early in 
the development, the result seems to be more critical for the patient. Modified after Zhu,Y et al.36. 
 
The genetics of MPNST 
 
A loss or a second-hit-mutation in remaining wild type allele of NF1 can already have happened in the 
development of benign neurofibromas, before MPNST is fully evolved. Some studies are showing that 
complete inactivation of NF1 has been found in benign plexiform neurofibromas39,40,41,42,43. This 
means that inactivation of NF1 is not sufficient for the development of MPNST. 
   Some other candidate genes for malignant transformation have been suggested, among these the 
TP53. Previous studies in mice have shown that compound heterozygous NF1+/- TP53+/- mice develop 
MPNST44,45. Also in the human setting, mutations of TP53 have been found in some MPNST46,47,48,49, 
but biallelic inactivation is rare50. Large gene rearrangements or deletions of the CDKN2A gene, that 
Neural-crest cells
Embryonic Schwann cell lineage Mature Schwann cell lineage
NF1 loss NF1 loss
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encodes INK4A and ARF, are frequent in MPNSTs, but is not present in neurofibromas51,52,76,77. ARF 
stabilizes TP53 by antagonizing the MDM2-mediated degradation53. Loss of ARF function therefore 
supports the idea that TP53-mediated pathways are important for the progression of MPNSTs. 
In addition loss of expression for KIP, a component in the RB1-pathway, has been identified in most 
MPNSTs (91%), compared with only 6% of neurofibromas54, indicating that the RB1-mediated G1/S-
checkpoint pathway might be important in the tumor progression. 
 
The genomes of MPNST are typically complex as shown by G-banding analyses56 (see below, and 
Table 1) and by fluorescence in situ hybridization techniques (see below)58,68,69,70. No pathognomonic 
markers have been identified but several recurrent aberrations are detected, possibly pinpointing target 
genes. In fact, common deletions of 9p21, initially shown by Lothe et al., 1996), strongly suggested 
CDKN2A as a target gene. Berner et al., confirmed this hypothesis in 1999. A CGH study also 
detected frequent gains of 17q sequences and showed recently that this may reflect an amplification of 
TOP2A, a known target for several chemotherapeutica (Skotheim et al., 2003). 
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Karyotype nomenclature and terminology 
 
Karyotypes in general are interpreted and described according to an international standard cytogenetic 
nomenclature71. 
In “Mitelman’s Database of Chromosome Aberrations in Cancer”(79) 45000 cytogenetically abnormal 
neoplasms are gathered. Here, the standard cytogenetic nomenclature is used, which will be described 
in the following. The autosomal chromosomes are classified according to size where the longest and 
largest chromosome is given the number 1, the second largest number 2, and so on. The sex 
chromosomes are called X and Y. Each chromosome has to arms, separated with the location of the 
centromere. The shortest of them is named p, the longest arm q. These arms are then divided into 
smaller regions, depending on specific landmarks. They include the ends of chromosome arms (the 
telomeres), the centromere, and the characteristic bands that appear either dark or light after staining 
with one or more of the different banding techniques. Each region is given a number, which starts 
from the centromere and outward along each chromosome arm. This way the two regions next to the 
centromere are both numbered 1, then the next region numbered 2, and so on. A band used as a 
landmark is by definition belonging entirely to the region distal to the landmark.  
 
So if a specific band is to be named, four items are required; 
-  1. the chromosome number,  
-  2. the arm symbol p or q, 
-  3. the region number, and 
-  4. the band number within that region.  
For example, 9q34 means chromosome 9, the long arm, region 3, band 4.  
 
Under prometaphase or early metaphase the chromosomal contractions are not as condensed as later in 
metaphase. Thus the banding pattern here is more complex, as several of the normal bands in 
midmetaphase are split into sub-bands. This gives higher resolution or better structure banding, and 
smaller details can be observed. The name of this sub-band is numbered like midmetaphase bands 
from the centromere and out, and is placed after a decimal point behind the original band designation. 
For example, the original band 1q42 may be subdivided into three sub-bands, labeled 1q42.1, 1q42.2 
and 1q42.3. If sub-bands are subdivided, additional digits, but no further punctuation, are used. For 
example: 1q42.12 
 
When describing a karyotype, the number of the total chromosomes is written first. In a normal cell 
the number is 46, but in cancerous cells the amount can vary quite a lot. After the number follows a 
Cytogenetic nomenclature 
 
28
 
comma (,) and then the sex chromosome is given. A normal male karyotype is therefore written 
46,XY, or a normal female 46,XX. 
 
Structurally altered chromosomes are given either a single or a three-lettered abbreviation. The 
number of the chromosome or chromosomes that are changed is written within parentheses. Following 
the chromosome is the symbol that describes the rearrangement. If two or more chromosomes are 
altered, the rule is that the lowest chromosome number is stated first. If one of the sex chromosomes is 
rearranged, this shall be listed first. The breakpoints are given within their own parentheses, and are 
specified in the same order as the chromosomes involved. A semicolon (;) is used to separate them. 
Figure 11 shows some examples of chromosome aberrations. 
 
- Translocation, t: this means that a chromosomal segment has moved from one chromosome to 
another, balanced or unbalanced. The translocation may or may not be reciprocal. 
• t(9;22)(q34;q11) describes two segments that has exchanged places. The distal part 
from chromosome 9q34 has moved to chromosome 22, where the distal part of 
22q11 used to be. This segment is now located at chromosome 9, distal to the 
breakage at 9q34.  
 
- Insertion, ins: a chromosomal segment has moved to a new, interstitial position in the same or 
another chromosome. The chromosome in which the segment is inserted is always specified first. 
• ins(5;2)(p14;q22q32) describes a breakage at band 5p14 in the short arm of 
chromosome 5 and that segment from 2q22 to 2q32 in the long arm of chromosome 
2 has been inserted between the two parts of the 5p14 breakage.  
• ins(2)(q13p13p23) is an insertion into the same chromosome from the segment 
between bands 2p13 and 2p23 into the long arm of chromosome 2 at 2q13. 
 
- Inversion, inv: This indicates an 180o rotation of a chromosome segment. In the karyotype 
46,XY,inv(3)(q26q29), breakage and reunion have occurred at bands 3q26 and 3q29. The 
segment between these bands is still present but in inverse orientation. 
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- Deletion, del: This means loss of a chromosome segment.  
• del(1)(q23) describes a terminal deletion with the break at band 1q23 and loss of the 
distal long arm segment. The remaining chromosome consists of the entire short 
arm of chromosome 1 and the part of the long arm that is between the centromere 
and band 1q23. 
• del(1)(q21q31) indicates an interstitial deletion with breakage and reunion at bands 
1q21 and 1q31. 
 
- Duplication, dup: An extra segment has been copied and inserted next to the original segment. 
The breakpoints describe the duplicated segment, e.g., dup(1)(q21q31). 
 
- Dicentric, dic: Is a structurally abnormal chromosome with two centromeres. 
 
- Double minutes, dmin: Chromosome fragments that are lacking a centromere are present in 
multiple copies. 
 
- Isochromosome, i: Isochromosomes consist of arms that are mirror images of one another. They 
are a result of misdivision of the centromere. 
• i(5)(p10) is one example of  an isochromosome for the short arm of chromosome 5. 
 
- Ring chromosome, r: The name comes from the ring structure that appears when breaks occur in 
both the short and the long arms, and these two reunite with each other. 
 
- Marker chromosomes, mar: Used to symbolize any structurally rearranged unknown 
chromosome. When the banding pattern is recognizable, however, the marker can be described by 
the standard nomenclature. The precise definition of a marker is a structurally abnormal 
chromosome in which no part can be identified.  
 
- When additional material of unknown origin is attached to a chromosome region or band, this 
may be described by the term add before the breakpoint designation.  
• add(19)(p13) describes some extra material that has become attached to band 
19p13, but the added segment is unknown. 
 
- Derivative chromosomes, der: Indicates any structural rearrangements that involve more than 
one aberration. Can be within a single chromosome, or involve two or more chromosomes. 
Cytogenetic nomenclature 
 
30
 
- Plus (+) and minus (-): These signs are placed before a chromosome number to indicate that it is 
either an additional chromosome (+), or that the whole chromosome is missing (-). They can also 
be placed after a symbol to indicate an increase or decrease in the length of a chromosomal arm.  
• 47,XY,+21 is then a male karyotype with 47 chromosome, including an additional 
chromosome 21,  
• 21q+ indicates an increase in the length of the long arm of one chromosome 21, 
better described using the add symbol, i.e., add(21)(q?). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 11. Chromosome alterations.
1. Loss of genetic material 
2. Gain of genetic material 
Deletion 
Monosomy 
Duplication
3. Relocation of genetic       
material 
Trisomy 
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Translocation 
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Aims of the study 
 
The overall aim of the project is to understand the molecular biology behind development of MPNST 
and to transfer this knowledge into clinical utility. 
 
MPNSTs usually have complex karyotypes showing numerous chromosomal aberrations. We 
have previously shown recurrent copy number gains and losses, including frequent loss of 9p 
and 13q, and gain of 17q. The target gene for the 9p losses is the CDKN2A and for the 17q 
gain there is evidence for TOP2A as one target gene. The target gene(s) for the 13q losses 
remains unknown, although the RB1 is a possible candidate. Based on this knowledge the 
present study has two specific aims.  
 
9 One was the localization and identification of additional target genes important in the 
development of MPNST on chromosome arm 17q.  
[This was searched for by a combination of metaphase and interphase FISH, as well as by G-band 
karyotyping.] 
 
9 The second aim addressed the potential importance of dysregulated cell cycle components in 
MPNST development. 
[This was investigated by analyzing in situ protein expression of a set of central cell cycle 
components in a large series of MPNSTs and in benign precursor lesions, neurofibromas, processed 
into a tissue microarray (TMA). This part of the study required a set of quality control experiments; the 
growth, harvest, and protein isolation of a series of cell lines to be used as a reference panel for 
antibody quality control by Western blotting. Secondly, the differential diagnoses of all MPNSTs were 
re-evaluated by reference pathologists prior to their inclusion in the TMA.] 
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Brief summary of the results 
 
Report 1. “Identification of breakpoints and copy number changes of DNA sequences at chromosome 
arm 17q in malignant peripheral nerve sheath tumors.” 
Probes mapping to a centromere close region and to the distal area of chromosome arm 17q, were used 
in FISH experiments on MPNST. This was done to map DNA copy number alterations in two areas of 
the long arm of chromosome 17, knowing that previous genome wide studies have found frequent 
gains from chromosome arm 17q in MPNST. The locus specific FISH results confirmed amplification 
of chromosome arm 17q sequences in two thirds of the MPNST series, among which half had 
chromosome 17 polysomy. The TOP2A-probe was amplified in 15 of the 29 tumors, which may partly 
explain the known overexpression of this protein in MPNST. Four tumors with normal copy number 
of the centromere and TOP2A showed gain at the distal locus, supporting the assumption of a second 
amplicon at 17q. Metaphase spreads were used for COBRA –FISH analysis of four MPNST, and 
breakpoints and marker chromosomes that included chromosome 17 were found in three and one 
tumors, respectively. The region of interest is currently narrowed down to 2Mb by FISH with selected 
BAC probes.  
 
Report 2. “Protein expression of cell cycle components in sporadic and neurofibromatosis type 1 
related malignant peripheral nerve sheath tumors” 
Expression data from 14 selected proteins in over a hundred tissue cores taken from MPNST were 
obtained in this study. A few neurofibroma samples were also included and evaluated against the 
MPNST results. We confirmed that TOP2A is expressed in the majority of MPNSTs. TP53 was not 
expressed to the same extent as expected from other studies. Generally the expression of cyclins and 
CDKs were high, leading to phosphorylated RB1 and G1/S transition. The cyclin-CDK-complex 
inhibitors had generally low expression, confirming the lost control of the cell cycle checkpoint at late 
G1-phase. 
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Discussion  
 
The results of the two parts of this study are discussed in the two reports. Therefore I will here focus 
my discussion on the advantages and limitations by the methods I have used as well as in relation to 
other alternative methodological approaches. The present study is based on previous results obtained 
by G-banding and CGH (Table 1), and we have here used COBRA-FISH as well as locus specific 
FISH. Thus, I found it reasonable to discuss in detail the impact of the various methods. 
 
Table 1. G-banded karyotypes of MPNSTs included in the present study. Performed in the laboratory of Professor Fredrik 
Mertens at the Department of Clinical Genetics, University Hospital of Lund, Sweden 
 
Tumor aberration 
1224-98 45,XY,t(10;17)(p10;p10),-20 
1274-98 47,XY,der(2)t(X;2)(q13;q37),+3,-9,add(15)(q22),dic(17;19)(p11;13),+18,+mar/45,X,-Y 
1934-98 51-60,XXX,+X,+?X,add(1)(q11),+der(1;3)t(1;3)(p12;q29)ins(1;?) 
(p12;?),-2,add(2)(q37),-3,add(4)(p11),-5,?add(5)(p11),-6,add(6)(q27), 
?der(8)t(1;8)(q25;p21),-9,-10,-10,?del(10)(q11),der(11)add(11)(p15) 
t(3;11)(p11;q24),der(11)add(11)(q23)de(11)(p13),-13,-13,-13,-14,-14,add(14)(p11),-15,-15,-15,-
16,i(17)(q10),der(?17)t(1;17)(q12;q25),-18, 
-18,-19,add(19)(q13),-20,-20,-21,-21,-22,-22,-22,+?r 
3201-99 40-43,XY,add(1)(p35),add(2)(p11),del(3)(q?22q?24),-5,I(7)(q10),-9, 
-9,-10,del(12)(q15),-14,-15,-16,-17,add(17)(p11),-18,+der(?)t(?;5) 
(?;q1?3),+2-3r,+mar 
3721-99 78-80,XX,-X,+add(1)(p11),+2,+3,del(3)(q25)x2,+4,add(4)(q35)x2,+5, 
der(5)t(?1;5)(p32;p15)x2,+6,+7,+8,-9,+11,+12,add(12)(q13)x2,+13, 
add(14)(q32)x2,-15,-15,+?add(16)(q?)(16)(q?),-17,+18,-19,-19,-19,+20,+21, 
+der(?)t(?;17)(?;q11)x2,+?r,2dmin 
2008-00 46,XX 
3687-00 55-59,XY,add(1)(p36),+2,add(2)(p21),-3,+ins(5;?)(q31;?),+add(7)(q31), 
+8,+9,-17,-17,+19,+19,+20,+20,+22,+der(?)t(?;12)(?;14) 
3869-01 
 
 
398-02 
45-46,XX,del(6)(p21),add(9)(q34),-13,?del(15)(q12q21,add(17)(p1?2), 
-18,+der(?)t(?;13)(?;q22),+mar 
 
45-46,XX,del(6)(p21),add(9)(q34),-13,?del(15)(q12q21,add(17)(p1?2), 
-18,+der(?)t(?;13)(?;q22),+mar / add(1)(p36) 
3043-02 64-69,X,-X,-Y,-1,der(1)t(1;?13)(q11;q12),+2,add(3)(q11),-5,add(5)(p15), 
-6,+add(7)(22),-8,-8,-9,-10,-11,der(11)t(?1;11)(p21;p14)x2, 
der(21)t(12;?15)(p12;15)x2,,+13,-14,-15,-15,-15,-17,-18,+20,-21,-22, 
+der(?)t(?;1)(?;q11)x2,+r,+4-6mar 
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Strengths and weaknesses of different cytogenetic screening 
methods  
 
Banding techniques 
 
Chromosome bands have a great practical significance. They are fundamental units of chromosome 
organization in which euchromatin alternates with heterochromatin, transcriptionally active DNA with 
nontranscribed DNA. This gives a resolution of nearly 400 bands in total, and remains today the 
technique of choice for initial 
screening for karyotypic 
abnormalities56, and are commonly 
used as a diagnostic tool for both 
solid tumors, hematological cancers, 
as well as for many other purposes 
(Figure 12). The strongest 
disadvantages with this method is 
that it requires metaphases, meaning 
that one need fresh tissue and that 
one need to grow the cells in short 
term cultures in order to get them to 
divide. This in itself usually 
demands quite large amounts of 
material, tissue samples. It also 
requires skills and experience to 
correctly interpret banded karyotypes.  
 
 
 
 
 
 
 
 
 
 
 
In the 1970s new banding techniques by Caspersson et al., 
and Yunis, gave so high resolution that chromosome pattern 
could now be described much more precisely. The methods 
first developed for this purpose used quinacrine mustard or 
quinacrine dihydrochloride to create transverse, fluorescing 
bands of variable brightness. The procedure is called Q-
staining after quinacrine and the resulting bands, Q-bands. 
Other techniques resulting in a basically identical banding 
pattern use the Giemsa dye, and are therefore named G-
staining methods and G-bands. R-bands give the reverse 
banding pattern of the G-bands, meaning R-bands are dark 
where G-bands are light. Other techniques stain only 
specific chromosomal structures, like the constitutive 
heterochromatin that gives C-banding and the telomere 
regions the T-banding. 
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Figure 12. A schematic 
representation of a human male 
karyotype. Each chromosome is 
shown by an ideogram (left), and 
an actual G-banded metaphase 
chromosome57. 
 
 
FISH-based screening techniques 
 
In the recent years multicolor based techniques have challenged chromosome banding, making 
pictures representing the entire genome using different colors when marking the chromosomes. This 
can be used to find possible chromosomal breakpoints and aberrations in, for example, cancer cells. 
Other techniques with higher precision can then be initiated.  
 
Multicolor-FISH 
 
If all of the human chromosomes are to be colored with painting probes of individual colors (Figure 
13), you'll need 24 differentially colored probe sets. The advantage of using multicolor-FISH when 
detecting and describing a chaotic karyotypic pattern, is that you get the same color on cryptic 
rearrangements and marker chromosomes (unknown pieces) as the original chromosome (Figure 14). 
One limitation, though, is that intrachromosomal changes can not be identified, and breakpoints are, at 
best, vague. 
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Figure 13. Multicolor FISH. Every human chromosome are 
colored by different colors.  
 
 
 
 
Figure 14. A translocation is easy to see when each 
chromosome has its own color. In this multicolor FISH 
example, the distal parts of chromosome arms 1q and 6q have 
exchanged places. 
 
 
Spectral karyotyping (SKY) 
 
SKY is a method that uses 24 chromosome specific probes, each labeled with a different combination 
of five fluorochromes. A single custom designed optical filter is needed to separate the fluorochrome 
combinations that give distinct colors to all of the 24 different chromosomes58,59,60,61. 
 
Multiplex-FISH (M-FISH) 
 
M-FISH is very similar to SKY, and also uses five spectrally distinguishable fluorochromes. But with 
M-FISH the detection of the different combinations needs a separate microscope filter for each of the 
five fluorochromes. The final result is then given after combining the images in a computer. Compared 
with SKY, M-FISH has therefore the advantage of permitting the visualization of the signal from each 
fluorochrome individually62,63,64. 
 
Combined binary ratio FISH (COBRA-FISH) 
 
COBRA-FISH needs only four fluorochromes to give 24 colors to all the chromosomes. This is 
achieved by using three fluorochromes pair-wise for ratio labeling a set of 12 chromosome painting 
probes, and then the last fluorochrome marks a second set of 12 probes65. This is used together with 
the combinatorial labeling described in the two other multicolor-FISH methods.   
Discussion 
 
37
 
Cross-species color banding (RxFISH) 
 
Another way of marking human chromosomes is by the use of cross-species color banding. 
Differentially labeled chromosomes from the gibbon ape are used as DNA probes66. Because of the 
98% resemblance in DNA sequences of the two species, hybridization will occur throughout the entire 
genome. But the advantage of using gibbon DNA is the many chromosomal rearrangements that have 
taken place during evolution, which gives a specific color banding pattern for each chromosome. A 
chromosome will not have only one color as in the other multicolor-FISH methods. As a result this 
technique can also be used to detect intra chromosomal rearrangements like deletions and inversions. 
 
Comparative genomic hybridization (CGH)                 
       
The technique does not require 
culturing for tumor 
metaphases, as in the FISH-
methods mentioned above. A 
limitation with CGH is that 
balanced translocations and 
inversions do not change the 
copy number of the DNA 
sequences, and will therefore 
not be detected. But in 
karyotypes that are complex 
containing many markers of 
unknown DNA sequences, 
CGH is a useful technique. 
 
 
 
 
 
 
 
 
CGH is a method to DNA copy numbers throughout the genome. For 
example, DNA from a tumor can be compared against reference 
DNA from normal cells, an approach first described by Kallioniemi 
et al. in 199267. Labeling the two genomes by different 
fluorochromes, and hybridizing them together onto normal 
metaphases gives intensity ratios along the genome, a representation 
of the DNA copy number ratio (Figure 15). Marking tumor DNA 
with green and normal DNA with red, changes as losses and gains in 
the DNA copy number will be shown by the color ratio of red and 
green. The image is transferred to the computer by a CCD camera 
and the data is addressed by specialized software. Since first 
published, several thousand samples have been analyzed by this 
method.  
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Figure 15. The principles of CGH.                       
In Comparative Genomic Hybridization, tumor                   
DNA (test) is labeled green, and reference DNA 
(normal) labeled red, and then cohybridised onto 
normal human metaphase chromosomes together 
with human Cot-1 DNA. A color ratio profile 
describes copy number changes in the test DNA 
relative to the reference DNA. 
 
 
 
 
 
 
 
 
 
 
Locus specific probes 
Since none of the methods written of above can obtain a high enough resolution to describe the whole 
genome down to single genes, an additional technique is often required. FISH analysis with locus 
specific probes can detect sequences present in only one copy in the genome. The technique is used in 
cancer genetics to investigate tumors for deletions, amplifications, inversions and translocations. It is a 
helpful tool in diagnosis of neoplasm since genomic aberrations often are disease-specific68,69,70. The 
possibility of using these probes in interphase cells allows work on archival genetic material and 
neoplasm with low mitotic activity. Interphase cells, however, give only information of deletions and 
amplifications. If translocations and inversions are to be detected, locus specific probes have to be 
used on metaphase preparations. In this chromosomal stage, the DNA sequences are assembled 
closely enough that their order along the chromosome can be seen in the microscope. Locus specific 
probes can then be used to determine exact breakpoint positions, or to detect the precise nature of 
specific rearrangements that may be masked in complex chromosomal abnormalities. 
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Argumentation behind the present locus specific FISH study. 
 
After the identification of an amplified or deleted region by a genome screening technique, one may 
use FISH probes to further narrow the region of interest. In our previous CGH study (Lothe et al., 
1996) we often saw amplifications from the chromosome arm 17q, and the large size of this amplicon 
implicated that numerous genes were present in too many copies. We therefore used a custom made 
cDNA microarray, covering all known and many predicted genes from chromosome 17, for detailed 
gene expression analyses in MPNST, and TOP2A was found to have the most highly upregulated 
expression of all genes on the array. Therefore, we decided to use locus-specific FISH to directly 
evaluate the DNA copy number of this gene in MPNST samples (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. FISH from a cell with normal copy numbers of the 
two probes tested. 
 
 
In addition, allelic imbalance studies have suggested a target region on the far distal part of 17q. Thus, 
we also selected a couple of distal probes for copy number evaluation. Finally, for the few cases we 
had remaining metaphase preparations from previous G-banding studies, we also performed COBRA-
FISH to resolve the karyotypes. 
Conclusion regarding choice of genome screening techniques 
 
FISH methods only complement standard chromosome banding analysis, and can so far not replace 
them. Every technique has its strengths and limitations. The best way to do a chromosome analysis is 
to start with chromosome banding, and then decide whether any of the FISH methods will be useful to 
give complementary answers to unresolved parts of the resulting karyotype. If only archival material is 
available, chromosome banding analyses can not be applied at all, and the CGH method in 
combination with interphase FISH will provide the best combination for genome analyses. We have 
here not dealt with the microarray based screening techniques. These offer in principle higher 
resolution than the chromosome based techniques. However, so far, the BAC clone microarrays have 
not been available for whole genome coverage, although whole coverage of specific chromosomes has 
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been published. In addition cDNA microarray or oligo arrays may be used as DNA copy number 
arrays. A limitation here is that only alterations of coding sequences are obtained. The costs and 
technical challenges have so far reduce the usefulness of these techniques compared with chromosome 
based analyses. However, as the technology develops, the applicability will be enhanced, and these 
new approaches may become the mostly used genome screening tools throughout the scientific 
community and also in diagnostics. 
 
Comparing protein analyses by Western blotting versus in situ 
hybridization 
 
Western blot analysis can be used to obtain information about alterations in the protein sizes caused by 
gene alterations or regulation at the expression level such as phosphorylations and dephosphorylations 
of proteins. The protein expression levels can also be measured and easily compared with other 
samples. A limitation with this method is that the subcellular localization of the proteins is lost. 
Another is that quite large sample material is needed for making the blot. 
When constructing a TMA only, small parts of each tissue sample are needed. With immunohisto-
chemistry, the protein expression is shown in situ, allowing detection of also the subcellular 
localization of the proteins. Immunohistochemistry has no information of the protein size. To check 
for intra-sample heterogeneity, replicate tissue cores from the same samples may be included in the 
TMA. If the sample is heterogeneous, having two phenotypically different cell populations, one can 
argue that the random sampling of only one tissue core will decrease the impact of the TMA results, 
not giving necessarily the best answer. Therefore, TMAs are not the platform of choice for diagnostics 
of individual tumors, but this tool has a tremendous advantage for comparisons of groups within large 
sample series. The power of simultaneously testing many samples ensures strong statistical 
distinctions between groups, even in the case of miss-classifications of a few tissues.  
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Future studies 
 
Chromsome 17 and expression profiling 
 
By a discovery-based research approach, whole genome analyses have identified several recurrent 
chromosomal aberrations in MPNST. The map positions of these anomalies, pinpoint the localization 
of potentially important target genes in establishment and progression of MPNST. Amongst the most 
common changes are gains of 17q sequences. Last year we showed that one of the genes targeted by 
this amplification is the topoisomerase IIα (Skotheim et al., 2003). The fact that the 17q gains often 
include large parts of the chromosome and due to previous allelic imbalance studies showing frequent 
distal 17q gains, we hypothesized that more than one 17q amplicon may contribute to MPNST. The 
present study has further supported this idea and has shown that upregulated TOP2A is indeed partly 
caused by gene amplification. We are continuing the search for the distal gene targets by FISH 
analysis using BAC probes covering breakpoints identified by other analysis with locus specific 
probes or with COBRA-FISH. Currently, an approximate 2Mb region of interest is identified. We have 
searched for upregulated expression in an existing dataset of 10 MPNST obtained by analysis of a 
cDNA microarray enriched with chromosome 17 genes. However, only very few genes in the region 
of interest was present on the array. Therefore, we decided to perform a gene expression analyses 
using Agilent 22k oligo array covering most genes in the genome. This data set will provide answers 
to several questions regarding the genetics of MPNST, not only the 17q-specific expression profile. In 
this new study design we have included precursor lesions of the plexiformed type, the MPNST from 
which chromosomal translocations involving chromosome 17 were detected, as well a set of MPNSTs 
from both NF1 patients and sporadic cases. If we detect dysregulation of genes in the specific 17q 
region that were identified by the BAC-probes, these genes will be considered good candidates for 
further hypothesis driven mutations analysis. 
Cell cycle 
 
The present thesis have provided a standard set of cell lines, representing germ cell tumors, 
mesenchymal- and epithelial-tumors, to be used, amongst others, for validation of the specificity of 
antibodies. The staining patterns of the antibodies are examined in large clinical series, of which the 
MPNST TMA is one. The in situ protein expression of central cell cycle components have been 
investigated in this study, and confirmed the lack of CDKN2A as characteristic to MPNST. It seems 
like once the CDKN2A is no longer functioning, the remaining proteins analyzed have a normal 
expression. Among the ones with CDKN2A expression, multivariate statistical analyses will be used 
further to examine the relationship among the markers as well as the relations to other data. We are 
now in the process of gathering all clinical information into databases, including type of treatment and 
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follow-up, for this purpose. In addition, most of the samples are analyzed for genome changes by high-
resolution CGH. The complete database of clinical and genomic information will, when finished, be of 
high value when related to the present protein expression data. 
Genome profiling 
 
The chromosome based genome screening methods are of course limited by the resolution of the 
microscopical evaluation of metaphase chromosomes. We plan to use a DNA microarray approach to 
further refine the genome picture of these tumors. Currently, the in-house BAC arrays with a 1Mb 
resolution are available. This resolution is 3-5 times improvement of the resolution from high-
resolution chromosomal-CGH for the detection of deletions, whereas the detection limit for 
amplifications will for the chromosomal-CGH depend on both the size, as well as the degree (number 
of copies) of the amplicon. Even a 5 Mb deletion in close proximity of a large amplicon may not be 
detected by chromosomal CGH. Thus, we expect by use of the BAC microarrays to gain novel 
information about the genomic changes of MPNST and neurofibromas. 
 
Signaling pathways 
 
The NF1 gene is a tumor suppressor which when inactivated leads to continuous activation of the RAS 
proto-oncogene. In general, one might expect that inactive NF1 may be mutually exclusive to mutated 
RAS or RAF, or visa versa. Due to the many exons of the NF1 gene, mutations have been poorly 
described in cancer, although the initial report on the cloning of this gene identified somatic mutations 
in various cancer types73,74,75. In addition, few, if any, MPNSTs have been analyzed for point 
mutations in the coding sequence. For MPNSTs from NF1 patients, a germline mutation of NF1 is 
expected, and a possible second hit is usually analyzed by deletion studies in the tumor. Among the 
sporadic cases of MPNST, even less information is available. However, it has been shown that 
inactive NF1 can be present in neurofibromas, indicating that additional changes are necessary for 
malignant transformation. With regard to this, one may hypothesize that mutated RAS or RAF may 
provide the cells with further malignant potential. To test the alternatives of mutual exclusiveness of 
these three genes or their combined effect in the early neurofibromas and late stages of MPNST, we 
will perform mutation analysis of all these genes. For the RAS and RAF genes, direct sequencing will 
be used, but for the NF1 gene we will establish the exon by exon screening analyses using the WAVE 
platform which is based on HPLC. Mutations will affect several down-stream pathways such as the 
MAPK and WNT-signaling. These pathways are also relevant in many other cancers. We will also test 
some of the components of the WNT-signaling pathway, for which we have established mutation or 
methylation assays, as well as examine the potential enrichment of dysregulated WNT components 
and/or downstream target genes from the expression microarray dataset described above. The latter 
may provide clues to novel targets for MPNST-development. 
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Last year, we showed that one of the contributing genes to MPNST is excess of the topoisomerase IIα 
(Skotheim et al., 2003). This protein is a known target of several drugs commonly used against cancer, 
and thus this discovery was of high interest. The fact that this cancer disease is rare in the population 
makes it hard to collect and examine large clinical series, not at least to evaluate the predictive value 
of biomarkers such as TOP2A since no standard treatment regime exists. Still, in a rather small sample 
series, TOP2A expression was found associated with poor prognosis. We have during the last decade 
collected fresh/frozen specimens relevant for various molecular studies as well as a series of formalin-
fixed archival material. In collaboration with the University of Lund, we have now a total of 106 
samples included in the TMA that provide us with a good tool to clinically validate the biomarkers 
identified in each of the above mentioned discovery-based and hypothesis-driven research approaches. 
By gaining novel insights into the underlying biology of this disease, and validate sets of relevant 
biomarkers, the project will aid in the current diagnostic and clinical challenges of this highly 
aggressive cancer disease of young adults.
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Identification of breakpoints and copy number changes 
of DNA sequences at chromosome arm 17q in 
malignant peripheral nerve sheath tumors. 
 
 
This study is part of a collaborative project between our group and the group of Fredrik 
Mertens, Department of Clinical Genetics, University Hospital of Lund, Sweden. I spent four 
weeks in the winter 2004 in the Lund laboratory being trained in karyotyping and performing 
the metaphase FISH analyses. The interphase analyses were performed in our own laboratory.  
 
Summary 
 
Based on previous studies that are implicating chromosome arm 17q amplifications in 
malignant peripheral-nerve sheath tumor (MPNST; Lothe et al., 1996, Mechtersheimer et al., 
1998, Schmidt et al., 1999 and 2000), fluorescence in situ hybridization (FISH) was used to 
establish DNA copy numbers of some selected loci (genes/clones) mapping to a region near 
the centromere, and to the distal area of chromosome arm 17q. The probes were hybridized 
onto interphase nuclei or metaphase preparations from MPNSTs from 29 patients. Sixteen 
individuals had the disorder Neurofibromatosis type 1 (NF1), whereas the remaining 13 were 
sporadic cases of MPNST. In addition, metaphase spreads were used for COBRA–FISH 
analysis of the whole genome in order to detect breakpoints and markers that include 
chromosome 17. The locus specific FISH results confirmed amplification of chromosome arm 
17q sequences in 2/3 of the MPNST series, among which half had chromosome 17 polysomy.  
The last 1/3 of the MPNST had no aberrations in any of the probes tested. TOP2A was found 
amplified at the gene level in 15 of the 29 tumors, partly explaining the increased expression 
previously detected at the RNA and protein level. Further, we identified a second amplicon at 
distal sequences on 17q, where as much as 19 of the 29 tumors were amplified. Five of these 
had normal copy numbers at the TOP2A/ERBB2 region and at the centromere. COBRA-FISH 
analyses detected MPNSTs with translocations involving chromosome arm 17q, and two 
known chromosomes namely chromosomes 1 and 10, and two unknown chromosomes. This 
study pinpointed a region of interest for further FISH analyses using BAC probes in order to 
identify gene targets. 
  50
Background 
 
Malignant peripheral nerve sheath tumors (MPNSTs) are rare neoplasms classified as 
mesenchymal tumors, because they often cause the same complications as soft tissue 
sarcomas and often develop in the extremities. Neurofibromatosis type 1 (NF1) is a common 
genetic disorder also known as the von Recklinghausen disease, and carriers have a germline 
mutation in the NF1 gene. The phenotypic features are several and development of multiple 
neurofibromas is one of them. These tumors are benign lesions that may become malignant, 
leading to MPNST. About 8-13% of the NF1 cases develop MPNST 28, which account for 
50% of all MPNST cases. 
No pathognomonic chromosomal translocation has been found in MPNST. Instead these 
malignancies often present complex karyotypes, but several recurrent aberrations are 
identified, including loss of 9p and gain of 17q. Identification of the target genes for these 
genomic changes will provide new understanding of the disease development and may aid in 
improving the many diagnostic and clinical challenges associated with this disease. 
With the strategy to first obtain a 
global view of the genomic 
changes in MPNST, we found 
that gain of 17q sequences was 
the most frequent aberration in a 
series of MPNST as assessed by 
comparative genomic 
hybridization (CGH; Lothe et al., 
1996). These gains often 
included large parts of 17q and 
we therefore went for a large 
scale expression study in order to 
detect dysregulated genes along 
this chromosome arm. We used a 
custom-made  microarray with 
636 cDNA clones from 
chromosome 17, and among the 
MPNST compared to the benign 
BOX 1: The TOP2A gene, located at 17q21-q22 
produces topoisomerase II-, a key enzyme in DNA 
replication, cell cycle progression and chromosome 
segregation. The nuclear enzyme is involved in 
processes such as chromosome condensation, 
chromatid separation, and the relief of stress that 
occurs during DNA transcription and replication. It 
catalyzes the breaking and rejoining of two strands of 
duplex DNA that allows the strands to pass through 
one another, thus altering the topology of DNA. Two 
forms of this enzyme exist as likely products of a gene 
duplication event. The gene encoding this form, alpha, 
is localized to chromsome 17 and the beta gene is 
localized to chromosome 3. The gene encoding for 
this enzyme functions as the target for several 
anticancer agents. 
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counterpart, neurofibromas, TOP2A, located at 17q21.2, had by far the highest expression 
level (Skotheim et al., 2003).This gene encodes a protein that is targeted by several drugs in 
cancer treatment. We did find a statistical association between TOP2A expression and poor 
patient survival. To further evaluate this target at the gene level we have in the present study 
evaluated the copy number of TOP2A in a Norwegian and Swedish series of MPNSTs. Since 
the CGH data showed large chromosome gains and since allelic imbalance studies have 
shown alterations at the distal end of 17q, we also studied distal 17q loci in order to verify the 
hypothesis of a possible second amplicon. We also analyzed ERBB2 (alias HER-2/NEU), 
located at 17q11.2 – q12, centromeric to TOP2A, and encoding a 185 kDa transmembrane cell 
surface glycoprotein. ERBB2 is a member of the tyrosine kinase family with a high degree of 
homology to the epidermal growth factor receptor (EGF-R), and amplification of ERBB2 has 
been reported in several other cancer types. Finally, a multicolor genome screening was done 
on a subset of the samples to identify possible breakpoints involving chromosome 17.   
 
Materials and methods 
 
Interphase FISH 
Tumor samples included in this study were taken from three benign neurofibromas and 
nineteen MPNST samples from 22 Norwegian and Swedish patients altogether. Ten of the 
tumors came from NF1 patients. Frozen sections of all samples were examined by a sarcoma 
reference pathologists. Only samples with confirmed MPNST diagnosis were included. We 
counted probe signals in nuclei from 100 cells of each tumor. 
 
Methods 
Freshly frozen tumor samples were cut in small pieces on a block of dry ice. Tumor fragments 
were immediately fixed in cold (-20oC) fresh methanol:acetic acid (3:1). The samples were 
centrifuged and the fixatives were renewed. The tissue fragments were then dissociated in 
80% acetic acid and left at room temperature for 2 minutes. One or two drops of the 
suspension were put on a pre-warmed slide laying on a slide warmer at 47oC, and dried for 5-
10 minutes. This gives a nice spread of the cell suspension. The slides were left overnight at 
room temperature.  
We examined the material with dual probes, TOP2A or ERBB2, together with a probe from 
the centromere of chromosome 17 (LSI TOP2A, SpectrumOrange TM / CEP 17, 
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SpectrumGreen: Vysis Inc, Downers Grove, IL), (ERBB2, Rhodamine / Chromosome 17 
Alpha-Satellite-probe, FITC: Qbiogene, Inc. Irvine, CA). A distal 17q-telomere probe was 
also examined (TEL 17q DNA probe, FITC: Qbiogene, Inc. Irvine, CA). Before hybridizing, 
the probes and chromosomes were simultaneously denatured. The slides were treated in a 
70% formamide solution containing 2 x SSC, and the probe mixture put in a water bath. They 
were both warmed at 73oC for 5 minutes. The slides were then dehydrated in a series of 
ethanol washes (70% ethanol for 2 minutes, 85% for 2 minutes, and 100% for 2 minutes) and 
dried on a 45-50oC slide warmer. A mixture of 1µl probe and 9µl hybridization solution was 
applied onto the slide, and a glass coverslip was sealed onto the slide. The slides were put in a 
prewarmed humidified box and placed in a 37oC incubator until the next day. The coverslips 
was then removed before the slides were washed for 3 x 10 minuets in 50% formamide and 2 
x SSC at 47oC. They were then put in 2 x SSC solution for another 10 minutes and then 
finally 5 minutes in 2 x SSC containing 0,1% NP 40. 
The slides were then air-dried away from light, counterstained with 10µl DAPI antifade 
solution, and sealed with a new coverslip. The nuclei were examined in a Zeiss fluorescence 
microscope and images were captured by a Cohu camera. Preparations of normal lymphocytes 
were used as controls for the hybridization conditions. 
 
Control Interphase FISH analyses using triple probe. 
 
To verify that the interphase-FISH results described above was comparable with the 
metaphase locus specific FISH analyses, we tested the triple probe used in the metaphase 
analyses on three samples that were already analyzed for the same loci but with dual probes 
(see above). 
 
Metaphase FISH 
 
Tumor samples included in this part of the study were taken from 10 cultured MPNSTs, all 
from Swedish patients. Six were tumors from NF1 patients. Three of the same samples were 
also included in the interphase FISH analyses. 
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Culturing of tumor cells 
 
Tubes containing MPNST cells, stored in the N2 tank, were heated in 34oC water. The cells 
were grown in RPMI-medium at 37 oC for appropriate number of days, and then added 
Colcemid (GIBCO) for 3-4 hours. Further, they were centrifuged for 10 minutes at 1000 rpm. 
after added trypsin. The pellet was dissolved in a hypertonic solution (KCl) for 25 minutes, 
and then washed in methanol:acetic acid solution (3:1). The solution was then spread on glass 
slides. 
 
Probe preparations 
 
Glass slides were treated in 60oC over night before submerged into 2 x SSC containing 500µl 
10% tween20 for 25-30 minutes, also at 60oC. The slides were washed in running water and 
dehydrated in a series of washes with increasing ethanol contents. 10mg/ml pepsin in 
0,01mol/l HCl solution was added onto the slides, which were coversliped and incubated for 
10 min on a 37oC slide warmer. The coverslip was removed before washing and dehydrating 
the slides. We examined the material with a multi color probe detecting both TOP2A and 
ERBB2 together with the centromere on chromosome 17 (LSI TOP2A/HER-2/CEP 17 Multi-
color Probe: Vysis Inc, Downers Grove, IL). We also used a single distal 17q-telomere BAC 
probe (see below) mapping to 17q25.3 (BAC-probe RP11-388C12: University of Bari, Italy). 
A total of 10µl probe solution, containing 7µl hybridization solution, 2µl water 1µl and probe, 
was applied onto the slides laying on a 37oC slide warmer and left there for 5 minutes with a 
glass coverslip away from light. Then the slides were heated to 74oC for 1.30 minute to 
denature the probes. The slides were put in a pre-warmed humidified box and placed in a 
37oC incubator for 16h to three days. The coverslips were removed, slides washed, 
dehydrated, and dried on the slide-warmer away from light. Finally, they were counterstained 
with 10µl DAPI antifade solution, before sealed with a new coverslip, microscopically 
evaluated. 
 
Metaphase FISH: BAC-probe procedure  
 
The BAC-probe RP11-388C12 was ordered from the University of Bari, Italy, and came in 
the form of Escherichia coli bacteria containing a plasmid with this probe. The E. coli was 
then grown in LB Medium (Bacto yeast extract 5 g; Bacto trypton 10 g; NaCl 10 g; H2O up 
to 1 Liter, Autoclave) to an appropriate amount, before extracting the DNA probes. The 
protocol is described here: 
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The E. coli was grown for 16-20 hours together with 30µl chlorampenycol because a 
resistance gene to this was incorporated in the BAC. 50ml E. coli was centrifuged for 20 
minutes at 4500 rpm. The pellet was resuspended completely in 3ml of GTE (50mM Glucose,  
25mM Tris pH=8, and 10Mm EDTA). Then 6ml of denaturation solution (0.2 N NaOH, 1% 
SDS, room temp), freshly made, and 5ml of 7.5M Ammonium Acetate were added. The 
solution was mixed immediately by inverting several times and left on ice for 10 minutes. The 
solution was again centrifuged for 20 minutes at 4500 rpm. Isopropanol (70% of the total 
volume) was added before centrifuged for 20 minutes at 4500 rpm. The supernatant was 
discarded, and the pellet washed with 5ml of 70% ethanol. Solution was centrifuged for 5 
minutes at 4500 rpm. The supernatant was discarded, and the pellet resuspended in 1ml of TE, 
added 500µl 7,5 mol/l Ammonium Acetate. This was put on ice for 1 hour, and then 
centrifuged for 20 minutes at 4500 rpm. The supernatant was discarded, and resuspended in 
3.5ml ethanol and left for 1 hour. Then the solution was centrifuged for 20 minutes at 4500 
rpm. The supernatant was discarded, and resuspended in 50-100µl of TE. The solution was 
left in room temperature over night. 
5µl primer was used for every 2000ng of genomic DNA, and put on 95oC water bath for 5 
minutes. The primer is universal in that it has a short sequence, and will therefore bind to the 
BAC at several locations. Then 2µl Florex (green colored dCTP, Amersham), 2µl Klenow 
polymerase (enzyme) and 17µl ATG-buffer were added and warmed at 37oC for one hour.  
The next day the reaction was stopped by adding Blue Juice, and centrifuged for 2 minutes at 
1500 rpm. The supernatant was discarded, and Cot. mix, ammonium acetate and ethanol were 
added, and left for one hour away from light. The solution was then centrifuged for 15 
minutes at 14000 rpm. The supernatant was discarded, hybridization solution added, and the 
probe was then ready for use. 
 
Approximately ten additional probes will, along with the use of COBRA-FISH, be performed 
in the laboratory of Fredrik Mertens on the chromosome arm 17q, in order to further describe 
the translocation breakpoints. 
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Results 
 
interphase FISH 
  
 Centromere 
- The number of centromeres is interpreted as the number of chromosomes, either partially 
or completely intact. 
- An increase in copy number was scored if the tumor had more than 1/3 of the nuclei 
showing three or more probe signals. 
- In order to correct for chromosome 17 polysomy, gene amplification was defined as the 
presence of 4 or more probe signals in at least 5% of the nuclei from a single tumor, plus a 
gene to centromere ratio of 2 or more. 
- 10 of 19 MPNST and 1 of 3 neurofibromas showed gain of centromere 17. 
 
 ERBB2 
- 9 of the 19 malignant tumors had increased copy number of ERBB2. All these had 
polysomy for chromosome 17.  
- 8 of these tumors also had cells that were amplified without having polysomy for 
chromosome 17. 
 
 TOP2A 
- 13 of the 19 malignant tumors showed an increase in copy number of TOP2A. 
- 10 of these 13 tumors had polysomy for chromosome 17, where 9 also had cells that were 
amplified without having polysomy for chromosome 17. 
- 3 of the 13 tumors had TOP2A gene amplification in at least 5% of the cells, without 
having the centromere probe amplified.  
 
 Telomere 17q 
- 13 of the 19 malignant tumors had in more than 1/3 of the cells an increased copy number 
of 3 or more signals of the telomere 17q probe. 
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Overall evaluation of the neurofibromas 
 
- 3 of the overall 22 samples in this study were benign neurofibromas. Two of these showed 
no alterations, whereas the last neurofibroma had gain of the centromere signals in 12% of the 
cells, and at the same time an increased copy number of more than 5% in all of the probes tested. 
This neurofibroma was therefore considered to be polysomic for the entire chromosome 17 in 
these nuclei. 
 
Summary of the MPNST interphase FISH results 
 
The interphase results are illustrated in Figure 1, and summarized in Table 1. Only 5 of the 19 
MPNST showed a normal copy number for all of the tested chromosome 17 probes. 
- 13 of the 19 malignant tumors had the 17q-telomere probe amplified. 
- 13 of the 19 malignant tumors had an increase in copy number of TOP2A. 
- 9 of the 19 malignant tumors had an increase in copy number of ERBB2. 
 
 
 
 
 
 
 
 
Figure 1A) A nucleus from an MPNST showing an increase in copy number of the  
TOP2A probe signal (six red spots), and a normal number of the centromere probe  
(two green spots). B) A MPNST nucleus having the normal copy number of both  
the TOP2A and centromere probes.  
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Table 1 (subgroups of MPNST based on interphase FISH probe signals on chromosome arm 17q). 
 
 Less than 67% of the cells have 2 probe signals. 
 More than 25% of the cells have 3 or more probe signals. 
 Polysomy for chromosome 17, meaning that more than 5% of the cells have 3 or more gene signals and 3 or more 
centromeric signals, in the same cell. 
 More than 5% of the cells have gene amplification, meaning 4 or more gene signals and only 2 centromeric signals, in 
the same cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample  Diagnose Centromere 17 ERBB2           TOP2A 17q-tel total 
      0 1 2 3 4 5+ 0 1 2 3 4 5+ 0 1 2 3 4 5+ 0 1 2 3 4 5+
3 (T-rygg) NF1 MPNST 1 9 51 35 3 1 0 1 26 17 32 24 0 4 36 27 22 11 2 6 46 2218 6 
6  NF1 MPNST 0 4 27 64 4 1 0 8 43 46 3 0 0 0 9 84 5 2 0 1 15 4628 10
14  NF1 MPNST 4 15 54 25 1 1 0 2 23 30 26 19 0 8 35 29 13 15 1 8 25 2929 8 
753-92 NF1 MPNST 0 7 51 20 19 3 0 5 60 21 9 5 1 1 11 32 18 37 0 2 18 3126 23
2406-94   MPNST 1 11 53 20 13 2 0 3 54 13 26 4 0 5 47 22 15 11 1 8 54 1015 12
246-96   MPNST 0 12 74 9 5 0 1 8 37 28 17 9 2 15 51 17 9 6 0 6 32 3018 14
12 NF1 MPNST. 0 9 87 5 3 0 0 3 41 56 0 0 0 4 57 20 13 6 0 1 62 1024 3 
11   MPNST 0 10 77 12 1 0 0 3 35 60 2 0 0 5 45 37 9 4 0 3 49 451 2 
650-90   MPNST 2 50 46 1 1 0 0 5 75 17 1 2 0 2 34 14 21 29 0 5 44 474 0 
763-91 NF1 MPNST 1 9 83 3 4 0 0 5 77 17 1 0 0 2 40 39 14 5 0 7 67 184 4 
1750-95   MPNST 0 8 91 1 0 0 0 7 92 1 0 0 0 0 25 0 28 47 0 2 37 1323 25
1615-94   MPNST 0 6 77 15 1 1 0 4 74 20 2 0 0 6 85 8 1 0 0 3 57 354 1 
5    MPNST 0 10 87 2 1 0 0 6 86 5 2 1 0 7 91 0 2 0 0 3 42 531 1 
9  NF1 MPNST 0 13 84 2 1 0 0 8 85 6 1 0 0 5 85 4 4 2 1 4 87 7 0 1 
8 NF1 MPNST 0 10 90 0 0 0 0 10 90 0 0 0 0 3 97 0 0 0 0 7 89 4 0 0 
13    MPNST 0 1 96 1 1 1 2 8 88 1 0 1 1 9 89 0 1 0 0 7 92 1 0 0 
2367-90 NF1 MPNST 0 10 89 0 1 0 0 12 87 1 0 0 0 10 88 0 2 0 0 4 88 6 2 0 
32-94 NF1 MPNST 0 7 91 1 1 0 0 3 97 0 0 0 0 4 90 5 1 0 0 5 88 7 0 0 
3420-95   MPNST 0 16 82 1 1 0 2 15 80 2 1 0 0 9 83 6 1 1 0 6 91 3 0 0 
3 (nates) NF1 Neurofibroma 0 4 82 7 3 4 0 1 87 4 2 6 1 10 76 5 6 2 0 8 79 7 4 2 
4 NF1 Neurofibroma 1 14 84 0 1 0 0 15 84 0 1 0 0 8 89 3 0 0 0 7 85 5 2 1 
12 (nf3) NF1 Neurofibroma 0 8 90 1 1 0 0 5 93 1 0 1 0 6 83 8 2 1 1 8 83 6 2 0 
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Metaphase FISH 
 
FISH on metaphase preparations do not provide the same large amount of interpretable nuclei as 
interphase preparations, and probe signals from 3-10 cells in each tumor were counted. Since 
metaphase chromosomes are condensed, the locations of the probes in the genome is seen. This 
way it is safer to state the actual copy number of the nucleus, if the same pattern is constantly 
repeated. Translocations can also be certified if the breakpoint is between two of the probe signals 
used. We also took the opportunity of using one of the multicolor-FISH techniques on a few 
selected tumor samples, (figure 2). The COBRA-FISH can establish different colors to all the 23 
chromosome pairs, and is therefore very useful for detecting translocations and describing other 
aberrations in a karyotype. There had already been performed G-banding of all these tumors, and 
some of the results listed under are interpreted with this karyotype in mind. The results of the 
metaphase FISH are presented in table 2.  
Table 2) Numbers of probe signals detected based on metaphase FISH on chromosome 17q.  
 
 
Patient Diagnose Centromere ERBB2 TOP2A 17q-telomere Translocations 
1934-98 MPNST NF1 2-3 4 4 4  
2150-02 MPNST NF1 2-3 2-3 2-3 5  
3721-99 MPNST NF1 3 2 2 8-9 t(?;17) 
3043-02 MPNST NF1 3 2 2 4  
3687-00 MPNST Sporadic 2-3 2 2 4 t(1;?)(p;?) 
3869-01 MPNST Sporadic 2 2 2 3 add(17p) 
3201-99 MPNST NF1 3 2 2 1-2 t(1;17)(p;q) + r17 
1224-98 MPNST Sporadic 2 2 2 2 t(10;17) 
1274-98 MPNST Sporadic 2 2 2 2 t(?;17)(?;TOP2A) 
2008-00 MPNST NF1 2 2 2 2  
 
 Green cells indicate copy number exceeding the set limitations (see above). 
- 2 of 10 tumors had increased copy number of all the probes tested. 
- 6 of 10 tumors had increased copy number of the 17q-telomere probe (Figure 3). 
- 6 of 10 tumors had increased copy number of the centromere probe. 
- 3 of 10 tumors had normal copy number of all the probes tested. 
- We found four tumors with possible translocations involving chromosome 17. In all these there 
had been a breakage along the chromosome arm 17q. The distal part of chromosome arm 17q 
was always translocated away from the centromere.  
- In one tumor, the TOP2A, but not the ERBB2, probe signal was translocated to another 
chromosome, implying a break point between ERBB2 and TOP2A. 
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- A translocation of the distal chromosome arm 17q and chromosome arm 1p was seen in one 
tumor. There was also a ring structure made up of chromosome 17 materials present in the 
karyotype of this tumor.  
- Another tumor had a translocation between chromosome 10 and chromosome arm 17q. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. COBRA FISH on MPNST case 
3869-01. The karyotype is showing 
alterations regarding an added sequence to 
chromosome 17, monosomies of 
chromosomes 7, 12, and 13, and one 
unknown marker chromosome on the bottom. 
The added segment on chromosome 17 is not 
specified, but looks like a part of 
chromosome 18.  
 
 
              
 
 
 
   
 
 
 
 
   
                 Telomere 17q probe (rp11-388c12)                               telomere 17q probe (rp11-388c12) 
      centromere 17 (Vysis).                                                            centromere 17 (Vysis). 
                   
Figure 3. The distal telomere probe on chromosome arm 17q has in this MPNST detected a highly increased copy 
number. The 17q telomere is here located also to chromosomes other than 17. 
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Control experiments of different probe combinations used on inter-, and meta-
phase preparations 
 
In summary, the results of the tumors analyzed by metaphase FISH differed slightly from the 
tumors analyzed by interphase FISH. There were fewer samples with increased copy number of 
TOP2A and ERBB2, than in the interphase cases. The telomere 17q probe was amplified in a wide 
extent in both cases, and polysomy of chromosome 17 was seen in about the same number of 
tumors. Therefore, for some tumors previously analyzed by interphase FISH, we tested the multi 
color probe on tumor metaphases. We found no differences in the results from the prior work done 
with the two dual probes. We then used freshly frozen material from some of the MPNSTs which 
we previously also had cultured and performed metaphase FISH on. This time we counted probe 
signals from 100 cells in interphase. The results were overall the same as the conclusion from the 
metaphase cells studied before. No tumor showed a high frequency of increased copy number of 
TOP2A or ERBB2, but the centromere probe was amplified in some tumors. 
 
Combined results of interphase- and metaphase FISH of MPNST 
 
All in all, 11 of the 29 MPNSTs on which we performed interphase- and/or metaphase FISH 
showed polysomy for chromosome 17. Eleven tumors had increased copy number of   ERBB2, 15 
tumors had increased copy number of TOP2A, and as many as 19 had an increased copy number of 
the 17q telomere probe (Figure 4). For 8 of the 29 MPNSTs, we detected no copy number 
alterations along 17q.  
We found no significant difference between MPNSTs from patients with neurofibromatosis type 1 
(n=16) and sporadic cases of MPNST (n=13) in relation to chromosome arm 17q copy number. 
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                                                     Centromere 17                      11 of 29    
                                                                                           17q11.2-q12 ERBB2             11 of 29    
 
                                                                                           17q21.1 TOP2A                    15 of 29 
     
 
 
 
                               
                                                                                           Telomere 17q                        19 of 29 
 
 
Figure 4) Increased copy numbers along chromosome arm 17q in MPNSTs.  
 
The number of MPNSTs with excess copies of the selected probes on chromosome arm 17q has an 
increasing trend towards the telomere. One third of the MPNSTs seem to have polysomy for the 
entire chromosome arm. Another third has parts of the 17q arm in extra copies, with the distal 
region always included. Often, the chromosome arm 17q is involved in a translocation with 
another chromosome, but it remains to be seen if this is a general pattern. The last third of the 
tumors had very few or no aberrations in any of the probes tested. 
 
Discussion 
 
It is generally agreed that cancer development is a multistep process involving natural selections of 
somatic mutations11,12. The karyotype of a cancer cell may look chaotic, but the genetic alterations 
in a specific tumor are not random. Cancers in different tissues have their own characteristic 
progression, and exposure to specific classes of carcinogens gives similar genetic profiles13,14. 
Several reports also reveal distinct patterns of genetic alterations in different tumors, thus implying 
that the carcinogenic process may proceed through alternative genetic pathways15. For instance are 
different genetic pathways to colon cancer closely related to specific segments of the colon16. But 
to differentiate between primary, pathogenetically essential, and secondary evolutionary 
aberrations is very difficult in solid tumors. At the time of diagnosis most solid tumors have 
already acquired several aberrations during tumor progression17. Telomeres can be directly 
involved in shaping the karyotypes of tumor cells. This happens if chromosomes connect in 
telomere fusions, followed by a breakage-fusion-bridge cycle18, or when essential genes regulating 
the cell cycle are mutated. 
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With this in mind, the results of the FISH on MPNSTs reveal two or three possible different 
pathways in the development of the cancer type. One has chromosome arm 17q sequences 
amplified during the progression, and is therefore taking advantage of some of the genes along this 
segment of DNA in the carcinogenic process. Since the other group of MPNST does not have this 
genetic alteration, it can’t be the direct cause of the malignant aggression that evolves in these 
cells. We know that biallelic mutations in NF1 are partly responsible for development of MPNST, 
but have also been found in benign neurofibromas19. This implies that NF1 inactivation is not 
sufficient for malignant transformation. Alterations within the TP53 pathway20-22 and the CDKN2A 
gene3-5, are also known factors in the development of MPNST. In fact, polysomy or partly gain of 
chromosome arm 17q, are common features in several sarcomas23,24. One MPNST had a 1;17 
translocation, and this genetic alteration has been seen in several neuroblastomas with gain of 17q 
and loss of 1p as a result of the translocation25,26. Ring chromosome of chromosome 17 material, 
as found in one MPNST, has also been found in dermatofibrosarcoma protuberans (DP), a tumor 
of low or intermediate malignant potential27. Within the group with 17q gains the two subgroups, 
one with a centromeric (TOP2A) amplicon the other with a distal amplicon, may also have 
different clinical impact. 
The two groups of MPNST with and without 17q gains as suggested in this study do not pinpoint 
the initiating event(s) of the carcinogenesis, but reveal important molecular information of 
diseaseprogression. One group, with gains of 17q sequences, could be associated with a poorer 
prognosis, as indicated by Schmidt, H. et al 9, and Skotheim et al., 2003, and hence have impact on 
the choice of adjuvant treatments. The potential associations with clinical variables for tumors with 
a centromeric or distal 17q amplicon remain to be seen.  
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Protein expression of cell cycle components in sporadic     
and neurofibromatosis type 1 related malignant               
peripheral nerve sheath tumors. 
 
Summary 
 
Previous studies have suggested that some central cell cycle components, in particular deficient p16, 
contribute to the development of MPNST. A selected set (n=11) of cell cycle components and 
proliferation markers (n=2) as well as the neurofibromin protein was analyzed by 
immunohistochemistry on a tissue microarray with tissue cores from 106 MPNSTs and 3 
neurofibromas. The tissue microarray sections were scanned with high resolution before visual scoring 
was done from the digital images. The expression data revealed that topoisomerase IIα (TOP2A) and 
Ki-67 are indeed expressed in most MPNSTs. Fewer tumors than expected had positive score of tumor 
protein 53 (TP53). Generally, expression of cyclins and CDKs were common among MPNSTs, 
leading to phosphorylated retinoblastoma (RB1) and G1/S transition. The cyclin-CDK-complex 
inhibitors were on the other side absent from most MPNSTs, confirming the suspicion of lost control 
of the cell cycle checkpoint at G1-phase. 
 
Background  
 
The molecular biological understanding of the development of malignant peripheral nerve sheath 
tumor (MPNST) remains mostly unknown. Patients with the autosomal dominant hereditary disorder 
Neurofibromatosis type 1 carry a germline mutation in their neurofibromin-producing gene NF1, and 
have a 5% risk of developing MPNST. This patient group accounts for 50% of all the MPNST cases1.  
The NF1 tumor suppressor gene maps to chromosome band 17q11.2, and the gene product functions, 
among other things, as a GTPase activating protein (GAP), thereby playing an important roll in the 
MAP-kinase pathway. The GAP function of neurofibromin regulates the activity of RAS by 
converting the active GTP bound state of RAS into the inactive GDP bound form2-4. RAS is a proto-
oncogene and if hyperstimulated it will, through ectopic activation of the MAP-kinase pathway, 
produce elevated amounts of oncogenic downstream target genes. Inactivation of both NF1 alleles are 
also found in the benign precursor lesions, neurofibromas, showing that additional genetic events are 
necessary for malignant transformation5-9. 
The MPNST karyotype is typically complex, but no pathognomonic structural aberration has been 
found10,11. Previous studies have suggested that mutated TP53 is important in the development of 
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MPNST12-14. However, the influence of TP53 itself is debated (15). CDKN2A (alias p16INK4A) has gene 
alterations in 50-75% of the MPNSTs16-18. The in situ protein expressions of these, as well as of a set 
of other proteins known to control the cell cycle, are examined in the present study. 
Materials and Methods 
 
Patients and samples 
 
Tumor samples from 70 patients were included in the study. Data from 44 patients were available. Of 
these had 22 patients a history of NF1, 13 males and 9 females, the age ranged between 14-71 years 
with and average of 31. Of the sporadic cases were 11 males and 11 females, and in the age range of 
20-85 years with and average of 50 years. 
 
Cell lines  
 
12 tumor types were cultivated in order to test for correct binding of the antibodies used in this 
experiment. The cell lines included four colon carcinomas (HTC116, Lovo, SW480, HT29) two 
prostates (PC-3, DU145), three testis (Tera2, NTera2, 2102Ep), one melanoma (129-melanoma), one 
fibrosarcoma (HT-1080) and one mammary gland (MCF-7). The cell lines were stored in -80oC  
before use. The cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (LGC 
Promochem, Boras, Sweden), supplemented with 10% bovine serum, glutamine and penicillin. The 
cell line cultures were incubated under standard conditions at 37oC in a humidified environment with 
5% CO2 in the air. When the monolayer was confluent, a split ratio of 1:3 was used for the 
subcultures. The cells could easily be detached by a trypsin solution. The medium was changed every 
other day after confluence. On the final day the cell culture were washed in PBS followed by 
centrifugation for 5 minutes at 1000 rpm. The supernatant was removed, and 1 ml PBS was added to 
the cell culture. The solution was sonicated (exposure to high frequency sound waves) for 15 seconds, 
followed by centrifugation at 14000 rcf in 20 minutes at 4oC. Fragments of the cell are collected into 
the bottom of the tube, while the proteins are now in the supernatant. They were stored in -70oC until 
use.  
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Antibodies 
 
The following antibodies (table 1) were used for in situ protein expression and controlled in a western 
blot procedure, performed on the cell lines described earlier.  
 
Table 1. Primary antibodies used in the present study. 
    
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
Antibody Antibody Specification Manufacturer Dilution 
 
TP53 
 
Monoclonal mouse IgG2a anti-
human (DO-1) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:1000 
TOP2α Monoclonal mouse IgG1 
topoisomerase II alpha (3F6) 
 
Novocastra Laboratories Ltd, 
Newcastle, UK 1:40 
CDKN2A Polyclonal rabbit IgG anti-human 
p16 (C-20) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:200 
CDKN2C Polyclonal rabbit IgG IgG anti-
human p18 (M-168) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:50 
CDKN1A Monoclonal mouse IgG1-kappa 
anti-human p21WAF1 (EA10) 
 
Oncogene Research Products 1:100 
CDKN1B Monoclonal mouse IgG1 anti-
human Kip1/p27 (clone 57) 
 
Transduction Laboratories, 
Lexington, KY, USA 1:100 
CCND1 Monoclonal mouse IgG2a anti-
human cyclin D1 (Ab-3) 
 
Oncogene Research Products 1:500 
CCND3 Monoclonal mouse IgG1-kappa 
anti-human cyclin D3 (DCS-22)
 
DAKO A/S, Glostrup, Denmark 1:50 
CCNE1 Polyclonal rabbit IgG anti-human
cyclin E (c-19) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:50 
CDK2 Polyclonal rabbit IgG anti-human 
cdk2 (M2) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:200 
CDK4 Polyclonal rabbit IgG anti-human 
cdk4 (C-22) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:50 
RB1 Polyclonal rabbit IgG anti-human 
Retinoblastoma (C-15) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:400 
Phospho-Rb Polyclonal rabbit anti-human 
phosphorylated Rb (Ser795) 
 
Cell Signaling Technology, Inc., 
Beverly, MA, USA 1:100 
NF1 Polyclonal rabbit IgG anti-human 
Neurofibromin (D) 
 
Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 1:40 
Ki-67 Monoclonal mouse IgG1-kappa 
anti-human (Ki-S5) DAKO A/S, Glostrup, Denmark 1:25 
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Tissue microarray construction and use. 
 
The tissue microarray (TMA) system was initially described in 199819. The present TMA was 
constructed by transferring 105 cylindrical tissue cores (0.6 mm in diameter) from 67 formalin-fixed 
and paraffin embedded MPNSTs, and 3 neurofibromas (one plexiformed) (Skotheim et al., 2003, and 
expanded with more samples; Figure 1). The TMA is stored at room temperature and 4µm sections are 
cut from the tissue microarray and transferred onto slides using the Instrumedics paraffin tape-transfer 
system (Instrumedics, Hackensack, NJ, USA). The slide is then UV treated for 30-40 seconds to make 
covalent bonds between the tumor material and the slide. The tape is removed after using a dissolvent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Tissue microarray (TMA) construction. Cylindrical core biopsies from each of the donor blocks (A) of formalin-
fixed and paraffin embedded tumors are transferred onto a recepient block (B) that becomes the TMA. 4µm sections (C) 
are made and each transferred onto slides that will be submitted to immunohistochemistry (D). (Figure reproduced Rolf I. 
Skotheim). 
 
 
The sections were deparaffinized in xylene and rehydrated via a series of graded ethanol baths  
(100% ethanol to wash away the xylene, followed by 95% and then 70%). Antigen retrieval was 
performed by heating in a microwave oven at 900W for 2 x 5 min using different buffer systems, 
(freshly prepared buffer consisting of either 0.1 m EDTA with 0.1% Tween pH 6.0, or XmM citrate 
buffer at pH 6.0). The antibodies used in the present study are listed in Table 1. Staining was 
performed with antibodies using the DAKO Envision kit (peroxidase/DAB). Endogenous peroxidase 
activity was blocked by applying DAKO’s peroxidase block for 5 minutes, before incubation with the 
primary antibody for 30 minutes at room temperature. Then, the secondary antibody, conjugated with 
HRP labeled polymer was applied, and incubated for 30 minutes. Staining is completed by a 5 minutes 
incubation with 3,3’-diaminobenzidine (DAB) + substrate-chromogen which results in a brown-
colored precipitate at the antigen site. Excess DAB was removed by distilled water, before the slides 
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were counterstained with haematoxylin, dehydrated in increasing grades of ethanol, cleared in xylene 
and mounted in depex. 
 
A schematic layout of the finished TMA construction is shown in Figure 2. The TMA contained in 
addition to the MPNST and neurofibromas 30 cores from tissues types other than discussed in this 
report. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic layout and contents of the TMA. The numbers refer to the different patients that the tumor samples 
were taken from. MPNSTs are shown in white, neurofibromas in yellow, and other tissues in grey (not analyzed in this 
study). 
   
Figure 3 is a picture from a program used after the TMAs were scanned at high resolution. The 
staining pattern can then be scored on a computer screen, as shown here for antibody TP53. Switching 
between the cases is done by clicking on the little picture in the upper left corner, showing the TMA 
layout as in Figure 2. For the cell cycle markers, the immunohistochemistry scoring was done by 
categorizing the tissue cores according to the frequency of positively staining nuclei. The result was 
interpreted as negative if less than five percent of the nuclei were stained. Tissue cores with a positive 
score were classified into three categories; weakly positive (5-10%), positive (10-50%) and highly 
positive (50-100%). 
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Figure 3. Scoring of the TMA. A screen shot of the software used to score immunohistochemistry on TMAs. The TMA 
sections were scanned after staining with the respective antibody.  
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Western blot analyses 
 
In order to verify function and protein binding of the antibodies in use for the in situ expression 
analyzes, a Western blot procedure was performed. This was done on the 12 cultivated cell lines, 
assuming that at least some of them would express the protein in question. 
 
Protein measurements 
 
The protein concentration of each sample was measured before Western blot analysis. This was done 
to ensure that equal amounts of proteins were loaded onto the separation gel before the 
electrophoresis. The procedure is based on a method first described by Bradford (1976) 20. The acidic 
dye, coomassie brilliant blue, binds to proteins with a subsequent change of its color when added to 
protein solution. The color change is a response to the protein concentration and can be measured with 
a spectrophotometer because of the switching of absorbance maximum from 465nm to 595nm. Protein 
concentration can be calculated using a standard curve. 
The lysis buffer (M-PER Mammalian Protein Extraction Reagent, Perbio, Pierce) was diluted 1:100 
with distilled water. The protein extract was made in the same proportions by adding 495µl distilled 
water to 5µl extract. 100µl and 200µl of the diluted protein sample were pipetted into two tubes and 
added 700µl and 600µl lysis buffer. Then 200 µl of Bio-Rad protein assay solution (coomassie 
brilliant blue G-250, Bio-Rad, Hercules, CA, USA) were added to each tube. To correct for 
background signals, two tubes with only 800 µl lysis buffer and 200 µl dye reagent were made. A 
standard curve was prepared by diluting bovine serum albumin (BSA) (Sigma) into six different 
concentrations, ranging from 0-4.0 µg/ml. Each standard dilution was added 200µl dye reagent and 
lysis buffer to a total volume of 1 ml. All standard and sample solutions were incubated in room 
temperature for at least 5 minutes before measured with a spectrophotometer (UV-1601 (Zhimadzu), 
Bergman, Lillestrøm, Norway) at 595 nm. The measurements were done within 30 minutes. A 
standard curve was plotted using the absorbance values (y-axis) against the known concentration of 
the standard samples (x-axis). The mean absorbance values of the samples were calculated and their 
protein concentrations were determined by using the standard curve. 
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Western blotting 
 
With the western blot technique a sample of proteins 
can be separated on a polyacrylamide gel, transferred 
to a nylon membrane, and then a specific protein can 
be detected. The process was first described by 
Towbin et al. in 1979, and further developed by 
Burnette in 1981 21,22.  
Denatured proteins are loaded onto a sodium dodecyl 
sulphate (SDS) polyacrylamide gel and separated, in 
accordance to the polypeptide size, by electrophoresis. 
A marker with a known molecular weight is loaded 
onto the gel with the rest of the samples, and used to 
estimate the size of the proteins after separation. The 
proteins are then transferred to a nylon membrane and 
treated with a blocking solution to saturate free 
binding sites and reduce non-specific binding. The 
antibody for the particular protein of interest is added 
in a solution so that it is covering all of the membrane. 
The antibody hybridizes to the antigen on the 
membrane that it recognizes. Unbound antibodies are 
washed away. The bound antibodies are detected by 
labeled secondary immunological reagents coupled to 
rabbit or mouse horseradish peroxidase (HRP).  The 
detection system used in this study is based on 
chemiluminescence (ECL detection reagent, 
Amersham, Oslo, Norway), a substance that produces 
light during a chemical reaction in room temperature. 
 
Western blot procedure 
 
The protein extract from the cell lines 
was thawed on ice and mixed with ice-
cold lysis buffer (M-PER Mammalian 
Protein Extraction Reagent, Perbio, 
Pierce). A molecular weight marker 
(High Range Rainbow Molecular 
Weight Marker, Amersham) was 
diluted with lysis buffer. 5µl gel 
loading buffer (7ml 0,5 M Tris-HCl 
pH 6,8, 1g SDS (Bio-Rad), 3 ml 
glycerol, 1,2 mg bromphenol blue 
(Sigma), and 0.93 g dithiothreitol 
(DTT)(Sigma)) was added to all 
samples and the marker. The samples 
were denatured by boiling for 3 
minutes, followed by a short 
centrifugation and left on ice until 
loaded on gel.  
 
SDS-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
The concentration of the poly-
acrylamide depends on the size of the 
protein that is to be detected. In a solid 
gel with a high percentage of poly-
acrylamide can even small proteins be 
separated. Two sets of gel types were 
used, one with 6% poly-acrylamide, 
and one with 12%. The stock solution 
was a 40% acrylamide/bis (29:1) 
solution (Bio-Rad), mixed with 10% SDS, 10% ammonium persulphate (APS, Bio-Rad) 1.5M Tris-
HCl pH 8.8, Tetramethylethylenediamine (TEMED), and distilled water. The gel mixture was poured 
between two glass plates in a vertical position with space left for a 4% stacking gel. A comb for 15 
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wells was immediately inserted into the stacking gel. One hour later the polymerization was complete, 
and the comb removed. The wells were then washed with buffer.  
The electrophoresis apparatus (Hoefer SE400 Sturdier Vertical Units, Amersham) was filled with 
electrophoresis buffer (25mM Trisma Base, 50mM glycine, 10g SDS) before mounting the gel and 
loading of the samples mixed with gel loading buffer and lysis buffer. The electrophoresis was carried 
out at a constant current at 30 mAmp. for 30-60 minutes. 
 
The proteins were then transferred from the gel onto a polyvinylidene fluoride (PVDF) membrane 
(Immobilon P-transfer, Millipore, Bedford, USA). Together with four pieces of 3MM Whatman filter 
paper (Merck, Darmstadt, Germany) the membrane was put in methanol, before arranged into a 
sandwich in a gel holder cassette. This was filled with transfer buffer (48mM Trisma Base, 39 mM 
glycine, 1.1 mM SDS, 200 ml methanol (Merck), and distilled water). The transfer was done at a 
constant current at 15 mAmp over night. 
 
If protein visualization was required the membrane was placed in a tray containing amido black 
staining solution (1g naphtol blue black (Sigma), 450 ml methanol, 100 ml 100% acetic acid (Merck), 
and distilled water to a total volume of 1l) for 5 minutes. For destaining, the membrane was placed in a 
destaining solution (800 ml methanol, 20 ml 100% acetic acid and distilled water to a total volume of 
1l) until the protein bands became visible and the membrane was not to dark. If the membrane was not 
used right away, the membrane was air-dried and stored in room temperature. Before hybridization a 
dried membrane was wet by methanol and washed in buffer.  
 
Antibody staining and scoring 
The membrane was blocked in a 10% dried skimmed milk solution (Nestle, Sandvika, Norway) solved 
in TBST buffer (20 mM Trizma Base, 0.5 M NaCl, distilled water and Tween-20 (Amersham)) for 60 
minutes. The primary antibodies were diluted with 5% blocking solution and hybridized with the 
proteins on the membrane either over night at 4oC, or in room temperature for 120 minutes. The 
membrane was then washed in TBST buffer before adding HRP-labeled secondary antibody (anti-
rabbit IgG HRP / anti-mouse IgG HRP, Invitrogen), diluted in 5% dried skimmed milk blocking 
solution. After one hour the membrane was again washed in TBST buffer. For visualizing, the HRP-
labeled secondary antibody ECL Western Blotting Detection Reagent (Amersham) was used as 
recommended by the supplier (Figure 4 and Figure 5). The membrane was placed in a film cassette 
together with an X-ray photo paper (Kodak, Amersham). The exposure time varied according to the 
staining intensities of the individual antibodies. The film was processed in an automatic developing 
machine (Curix 60, AGFA, Mortsel, Belgium). 
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Figure 4) Principles of ECL Western blotting. The primary antibody binds to a specific protein, and  
is visualized by binding of a horseradish peroxidase (HRP) conjugated secondary antibody.  
The detection system used in this study is based on chemiluminescence (ECL detection reagent,  
Amersham, Oslo, Norway); a substance that produces light during a chemical reaction in room  
temperature (figure modified after Amersham’s ECL Western blotting instructions guide).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5) The chemiluminescence reaction. Luminol in the presence of chemical enhancers such as 
phenols, is in an excited state after oxidation, catalyzed by the HRP/hydrogen peroxide. Luminol then 
decays to ground state via a light-emitting pathway (figure modified after Amersham’s ECL Western 
blotting instructions guide). 
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Scoring 
 
Protein sizes were checked against the rainbow colored  
protein molecular weight marker (Amersham, Figure 6). The  
expression signals of the proteins on the Western blot films were  
scored as: 
0        -    no expression 
+        -    weak expression 
++     -     moderate expression 
+++   -     strong expression 
(+)     -      no wt expression 
       R       -      rearranged protein 
       ns      -      not able to score  
                                                                                                                          Figure 6. Rainbow marker 
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Results 
 
In situ protein expression using tissue microarrays  
 
Tumors with nuclear staining in more than 5% of the neoplastic cells were classified as positive, while 
those with less than 5% were considered negative. Most tumors had replicate tissue cores on the tissue 
microarray, and a tumor was considered positive when one or more of its tumor tissue cores were 
positive. The results of the in situ expression analyses are summarized in Table 2. 
 
Table 2. Percentage of the MPNST nuclei with positive staining for a set of antibodies. 
Percentage of stained nuclei  
0 % 1-5 % 5-10 % 10-50 % 50-100 % number of samples 
Antibody Percentage of tumors with same level of expression 
CCND1 9 % 27 % 22 % 28 % 14 % 65 
CCND3  59 % 13 % 9 % 12 % 7 % 67 
CCNE1 53 % 17 % 15 % 12 % 3 % 59 
CDK2 76 % 8 % 11 % 5 % 0 % 64 
CDK4 0 % 0 % 0 % 49 % 51 % 43 
Ki-67 24 % 15 % 17 % 35 % 9 % 66 
TOP2A 4 % 11 % 9 % 45 % 31 % 45 
CDKN1A  (p21) 80 % 9 % 5 % 5 % 1 % 66 
CDKN1B  (p27/Kip1) 56 % 24 % 6 % 12 % 2 % 63 
CDKN2A  (p16INK4A) 50 % 11 % 9 % 24 % 6 % 64 
CDKN2C  (p18INK4C) 32 % 42 % 20 % 6 % 0 % 50 
RB1  0 % 2 % 11 % 49 % 38 % 63 
RB-ph 5 % 5 % 15 % 58 % 17 %            40 
TP53 87% 0 % 4 % 5 % 4 %            55 
  
The results of this table are visualized in Figure 7. The three categories of expression are  
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 Figure 7. Graphical representation of protein expression in MPNST. 
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illustrated with different shades in grayscale, the darkest being the highest degree of expression, grey 
meaning moderate expression, and light grey meaning weak expression. As mentioned earlier the 
TMA slides with the in situ protein expression was scanned, and the  
 
Antibody: TP53,     0% staining                           10-50% staining                  50-100% staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody: RB1,  1-5% staining                           10-50%  staining                  50-100% staining  
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody: CDK4, 1-5% staining                          10-50% staining                  50-100% staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. MPNST tissue microarray, immunohistochemical staining. For a collection of the analyzed proteins, 
representative tissue cores of one negative stained neoplasm, one moderately stained and one highly stained neoplasm are 
shown. The three antibodies tested here are TP53, RB1 and CDK4. 
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results were visually scored from digitized images. Figure 8 shows examples from this technique, and 
has three pictures from each of the antibodies TP53, RB1, and CDK4. The examples in the first 
column are images scored as negative due to less than 5% staining of the tumor nuclei. The examples 
in columns two and three have expression of the proteins in 10-50% and more than 50% of the nuclei, 
respectively. 
For cytoplasmic protein expression, we used another set of categories; i.e., no expression, moderate 
expression and high expression (Table 3). 
 
 
Table 3. Staining of cytoplasma in MPNST. 
Antibody Nonexistent Moderate expression High expression
CCND1 76 24 0
CCND3 99 1 0
CCNE1 84 10 6
CDK2 79 21 0
CDK4 76 14 10
CDKN1A  (p21) 100 0 0
CDKN1B  (p27/Kip1) 76 24 0
CDKN2A  (p16INK4A) 98 1 1
CDKN2C  (p18INK4C) 42 48 10
Ki-67 99 1 0
RB1  99 1 0
RB-ph 99 0 1
TP53 96 4 0
NF1 27 54 19
 
We also analyzed three neurofibromas, of which one was of the plexiform type. The neurofibromas 
were analyzed and scored in the same manner as the MPNSTs (Table 4). 
 
Table 4. Degree of nuclear staining with a set of antibodies on neurofibromas. 
Percentage of stained nuclei 
  
  0 1-5% 5-10% 10-50% 50-100%
Antibody Percentage of tumors with same level of expression 
CCND1 100 %     
CCND3 33 % 33 % 33 %     
CCNE1 100 %         
CDK2 67 %   33 %     
CDK4 67 % 33 %       
CDKN1A  (p21) 33 % 33 %   33 %   
CDKN1B  (p27/Kip1) 100 %         
CDKN2A  (p16INK4A) 67 %   33 %     
CDKN2C  (p18INK4C) 33 %     33 % 33 %
Ki-67 67 % 33 %       
RB1      33 % 67 %   
TP53 100 %         
NF1 (cytoplasma)   66 % 33 %     
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The most highly expressed gene on chromosome 17 in MPNSTs as compared to neurofibromas, has 
been found to be Topoisomerase IIα (TOP2A)46. The detection of TOP2A expression in 85% of the 
MPNSTs in the present study was therefore not surprising, and is found highly expressed in other 
studies too51. 
 
Published frequencies of CDK4 positive MPNSTs have been ranging 4 % (48) to 46% (51). In the 
current study, 100% of the MPNSTs had high CDK4 expression, whereas only 16% expressed CDK2. 
In the neurofibromas, there were no CDK4 expression, but one of the three was weakly positive for 
CDK2. 
 
Expression of RB1 was measured with two antibodies. The “RB1” antibody is binding to both 
phosphorylated RB1, and none-phosphorylated RB1, while the “RB-ph” antibody is only binding the 
phosphorylated RB1. 98% of the tumors were positive for the “RB1” antibody, whereas and 90% were 
positive for the “RB-ph”, an eight percent difference. These 8% represent unphosphorylated RB1. The 
fact that 90% of the tumors had phosphorylated RB1 indicates that the checkpoint between G1 and S-
phase is absent, and hence the restriction of E2F-transcription factors is lost. Overexpression of RB1 in 
MPNST has also been previously reported48,49. 
 
TP53 activates CDKN1A (p21) in response to DNA damage and cellular stress50. Other studies of 
sarcomas, including MPNST, have observed TP53 expression in 28%(49)-83%(57) of the analyzed cases. 
In this study, however, only 13% of the MPNSTs had TP53 expression. None of the neurofibromas 
had any expression of TP53, which is in line with previous studies17,47,48,51,52.  
 
A relatively low frequency (29%) of CCND1 expression in MPNSTs has been reported in previous 
immunohistochemical analyses47,49. In this study, 64% of the MPNSTs expressed CCND1. Only 28% 
of the MPNSTs expressed CCND3, and 30% CCNE1.  
None of the neurofibromas expressed CCND1 or CCNE1, but one of the three expressed CCND3. 
 
The NF1-gene product, neurofibromin, is expressed in the cytoplasm. By immunohistochemistry, NF1 
expression was detected in 73% of the MPNSTs, but only in one of three neurofibromas. Inactivation 
of both NF1 alleles is thought to influence on the malignant progression of the tumor. Therefore is the 
frequent expression of NF1 in the MPNSTs unexpected. The NF1 antibody (Santa Cruz) is raised 
against a peptide mapping to the carboxy terminal domain of the human protein. The antibody can 
detect proteins even if a large part is missing, or specific domains are non-functional, due to mutations 
in the gene. The expression of proteins with the catalytic GAP-related domain intact or functional can 
therefore be lower than detected. 
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In this study both CDKN1A and CDKN1B had expression in 11% and 20% respectively, of the 
MPNST in the nuclei, whereas CDKN1B had high cytoplasmic staining in 24% of the MPNSTs. This 
is lower expression for CDKN1A than reported before49. CDKN1B has normally weak expression in 
MPNST49,51, but a stronger immunostaining in the cytoplasm in MPNST 49,51. 
Of the neurofibromas one of three showed positive CDKN1A immunostaining. CDKN1B had no 
expression. 
 
Thirty-nine percent of the MPNSTs had expression of CDKN2A (p16INK4A). In other studies 
expression has been reported lower (4-9%)18,48, and higher (46%)51.  
One of the three neurofibromas had some expression of CDKN2A.  
 
CDKN2C (p18INK4C) was expressed in 24% of the MPNSTs, and showed high expression in two of the 
three neurofibromas.  
 
Ki-67 showed protein expression in 59% of the MPNSTs, a result that match another study 49. 
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Results of the Western blotting 
 
The Western blotting results of the cell lines are shown below for each protein analyzed (Figures 9-
18). The known functions of the proteins are indicated in a text box under each Western figure. The 
weak expression of some proteins in these western blotting, does not mediate with the in situ 
expression done on the TMA. The western blotting serves as a test for whether the antibodies bind to 
proteins of correct size, and whether the binding is specific. 
                                                                                      
 
TOP2A  
 
 
 
 
 
 
Figure 9. TOP2A. The wild type protein is 
expected to be of 174 kDa, and was clearly 
expressed in most cell lines. Seven cell lines had strong 
expression (SW480, NTERA2, 2102Ep, 129-
melanoma, HT-1080, PC-3, Du145) while four had some 
expression (Lovo, HTC116, TERA2, MCF-7). One colon 
cell line, the HT29 showed two weak fragments of 
TOP2A, one wt at 174kDa and one smaller 
truncated protein at 160 kDa. This suggests a 
possible rearrangement of the gene due to a 
mutation. 
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174 kDa 
 
 
 
 
  
Topoisomerase IIα is 
predominantly present in 
proliferating cells and is modified 
in M phase by phosphorylation at 
specific sites. This appears to be 
critical for mitotic chromosome 
condensation and segregation32. 
TOP2A is also the molecular target 
of several cancer 
chemotherapeutics. 
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CDK2 
 
 
 
 
 
 
 
Figure 10. CDK2. The protein is 34 kDa, and was found 
to be expressed strongly in all of the cell lines. A 32kDa 
protein did also show up on the western blotting.  
 
 
 
Cdk4 
 
 
 
 
 
 
 
 
 
Figure 11. CDK4. The wild type protein is 34kDa, 
and was found to be expressed in all of the cell 
lines. Bands at 24kDa and 25kDa proteins were 
also seen for all cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
+    +      +                                         +      +       +       +       + 
+    +      +       +      +       +      +      +      +       +       +       + 
+    +      +       +      +       +      +      +      +       +       +       + 
CDK2 binds CCNE1 and the 
complex phosphorylates RB137-38. 
CDK2 is also essential for the G2 
to M transition in cell cycle 
control39. 
 
45 kDa 
 
34 kDa 
 
 
25 kDa 
24 kDa 
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CDK4 forms holoenzymes with D-
type cyclins early in G136, and 
triggers transitions through late G1, 
by phosphorylating RB1.  
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Figure 12. TP53. The wild type protein is 53kDa, and was 
expressed in 8 of the 12 cell lines. HTC116, 129- melanoma, 
HT1080, PC-3 and Du145 had moderate to strong expression 
compared to the four SW480, TERA2, NTERA2, and 2102Ep. 
Some products of 43-44kDa were found expressed in HT1080, 
PC3 and Du145. It is possible that these are smaller truncated 
proteins due to rearrangements of the gene. 
 
 
 
 
CCND1 (cyclin D1)                                                                                  
 
 
 
 
 
 
 
 
 
Figure 13. CCND1. The known protein is 33 kDa, and 
was found to be expressed in most cell lines. HT29 and 
NTERA2 showed no expression, but the blot is not 
optimal and has weaker signals than desirable, it is hard to 
say. It was not possible to score TERA2 due to a bright 
spot interfering.   
 
 
The D family of cyclins appears 
in early G133. They form 
holoenzymes with CDK4 and 
CDK6 whose activity triggers 
transitions through late G1, by 
          +                                                           + 
          +                                                   +      +      +     + 
 0       +       0        +      +      +      +       +      +      +     +     0    
 
53 kDa 
44 kDa 
  
 
TP53 is a tumor 
suppressor protein that 
upregulates growth arrest 
and apoptosis-related 
genes in response to stress 
signals, and therefore 
controls programmed cell 
death and cell 
differentiation40,41. 
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CCND3 (cyclin D3) 
 
                                                                                                              
 
 
 
Figure 14. CCND3. The wild type protein is 33 kDa, and had mostly weak expression in most cell 
lines. Lovo, TERA2 and NTERA2 had no expression. This blot had 18 minutes exposure time with the 
X-ray photo paper, still the protein expression signals were weak. 
 
 
NF1 
 
 
 
 
 
 
 
 
Figure 15. NF1. The wild type protein is 
250kDa, and was expressed in 8 of the 12 cell lines. 
Lovo, HTC116, HT29 and MCF7 did not 
express any NF1. A 240kDa truncated protein was 
found expressed in the melanoma cell line (129-
melanoma) and can be a mutation due to a 
rearrangement in the gene. 
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Although little is known regarding 
the function of NF1, the homology 
with the catalytic domain of proteins 
with GTPase activity suggests that 
NF1 may also interact in vivo with 
RAS proteins2-4. 
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 CCNE1 (Cyclin E) 
 
 
 
 
 
 
 
 
Figure 16. CCNE1. The wild type protein is 47 kDa, 
and was expressed in all cell lines, except for one colon 
cell line, SW480. In addition eight cell lines had weak 
expression of a protein with a protein size at 40 kDa, 
(Lovo, HTC116, HT29, 129-melanoma, HT1080, PC-3, 
Du145, MCF-7). Two cell lines had also 
expression of a 70 kDa protein, (HTC116 and PC- 3).  
  
RB1 
 
 
 
 
 
 
 
 
Figure 17. RB1. The wild type protein size is 
106kDa and was expressed in nine cell lines. 
Lovo and HT29 expressed only a second band at 
65 kDa, a band that were expressed in all cell 
lines, except in the prostate cancer cell line 
Du145, which had no expression at all. 
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CCNE1 has its maximal level near 
the G1/S boundary, after the cyclin D-
CDK4 complex has initiated RB1 
phosphorylation. CCNE1 then binds 
to CDK2, and the complex continues 
the RB1 phosphorylation, forming a 
positive feedback loop37-38. 
 
106 kDa 
 
 
 
  65 kDa 
  
                          +                  +                  +       +        +     
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The Retinoblastoma gene encodes a protein 
that is a potent inhibitor of E2F activation. The 
protein is phosphorylated from S to M phase of 
the cell cycle and is dephosphorylated in G1 45. 
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Ki-67   
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Ki-67.  The two wild type protein sizes at 
395kDa and 345kDa were detected in four of the cell 
lines (NTERA2, 2102Ep, PC-3 and Du145). Some 
other bands were also detected in these cell lines, and 
were also expressed in HTC116, SW480, 129-
melanoma and HT1080. Lovo, HT29, TERA2 and 
MCF7 had no expression of KI-67. 
 
For the inhibitors with a protein size smaller than 20 kDa, i.e. CDKN2C (p18INK4C) CDKN2A 
(p16ink4) CDKN1A (p21) and CDKN1B (p27/Kip1), were the Western blots not optimal, even after 
repeated hybridizations. We believe this is a technical problem. We did decide to analyze the 
antibodies on the TMA, knowing that the antibodies had been successfully used in a previous Western 
blot study of primary MPNST (Ågesen et al., J Neuropathol Exp Neurology in press).   
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The proliferation marker Ki-67 (395kDa 
and 345 kDa) is expressed during all 
active phases of the cell cycle, G1, S, G2 
and M-phases, but it is absent in resting 
cells in G0 phase44.  
 
 
 88
Discussion 
 
TOP2A is expressed in most MPNSTs. There is an association between high expression of TOP2A 
and poor patient survival. For patients with TOP2A expressing MPNST, only 38% were still alive five 
years after diagnosis, but among patients with TOP2A negative MPNST, 83% were still alive46.  
 
Of the cyclins tested, CCND1 had the highest expression in the MPNSTs (64%), whereas CCND3 and 
CCNE1 were expressed in about a third of the tumors. The D-type cyclins form complexes with and 
functions as a regulatory subunit of CDK4 or CDK6. An active CDK4/6-Cyclin D complex is required 
for cell cycle G1/S transition. CDK4 was expressed in 100% of the tumors, meaning that the 
checkpoint of the G1/S transition is probably out of control, again leading to an ongoing cell 
proliferation. This is confirmed with the findings of phosphorylated RB1 in 90 % of the tumors. The 
product of high CDK4 and CCND1 expression is phosphorylated RB1, followed by the activity of E2F 
transcription factors, and G1/S transition.  
 
TP53 activity was found in only 13% of the tumors. The gene is expressed after cellular stress or DNA 
damage, and without TP53’s control of cell cycle arrest it is easier for a tumor to grow. The low 
expression of CDKNA1 and CDKN1B compared with other studies49,57, can be a consequence of this, 
which normally would be activated by TP53, and inhibit cyclin-CDK-complexes.  
 
CDKN2A and CDKN2C are also cyclin-CDK-complex inhibitors. CDKN2A was found expressed in 
39% of the MPNSTs, which is more frequent than in other reports18,48,51, whereas CDKN2C was 
expressed in 26%. It is possible that with low expression of CDKN2C, CDKNA1 and CDKN1B, G1/S 
transition control is lost, and that the amount of cyclins and CDKs exceeds the inhibitory effect of the 
relative high CDKN2A expression alone.  
 
The quality of the expression scorings will be controlled by a pathologist.  The total clinical database 
are under construction.  After this is achieved the protein expressions will be evaluated in relation to 
each other as well as to the clinical variables. 
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